{"gene":"NR4A3","run_date":"2026-04-29T11:37:57","timeline":{"discoveries":[{"year":2007,"finding":"Abrogation of both NR4A3 (Nor-1) and NR4A1 (Nur77) in mice leads to rapidly lethal acute myeloid leukemia involving abnormal expansion of hematopoietic stem cells and myeloid progenitors, decreased expression of AP-1 transcription factors JunB and c-Jun, and defective extrinsic apoptotic (Fas-L and TRAIL) signaling, establishing NR4A3 as a tumor suppressor of myeloid leukemogenesis.","method":"Genetic knockout mouse model (double Nr4a1/Nr4a3 knockout) with phenotypic readout (AML development, HSC expansion, apoptotic signaling analysis)","journal":"Nature medicine","confidence":"High","confidence_rationale":"Tier 2 — clean KO with defined cellular phenotype, replicated in human AML patient samples","pmids":["17515897"],"is_preprint":false},{"year":2000,"finding":"NR4A3 (Nor1) is expressed in the pituitary gland and adrenal cortex; ACTH and angiotensin II treatment induces Nor1 expression in adrenal fasciculata cells; Nor1 activates steroidogenic enzyme genes (e.g., P450c21) through binding to NGFI-B response element (NBRE) promoter sequences; transcriptional regulation of Nor1 in adrenal cells depends on protein kinase A and protein kinase C cascades.","method":"Transactivation reporter assays, binding experiments with NBRE and NurRE sequences, pharmacological inhibition of PKA/PKC pathways","journal":"Endocrinology","confidence":"Medium","confidence_rationale":"Tier 2 — functional reporter assays and pharmacological dissection, single lab","pmids":["10875239"],"is_preprint":false},{"year":2005,"finding":"Prostaglandin A2 (PGA2) acts as a transactivator for NR4A3 (NOR1) by directly binding to the ligand-binding domain (LBD) of NOR1 and activating NOR1-dependent transcription; LBD-deleted NOR1 shows little transcriptional activation by PGA2.","method":"GAL4-based reporter system, direct LBD binding assay, transgenic mouse-derived spleen cell sensitivity assay","journal":"Biological & pharmaceutical bulletin","confidence":"Medium","confidence_rationale":"Tier 1-2 — direct LBD binding and reporter assay, single lab","pmids":["16141523"],"is_preprint":false},{"year":2001,"finding":"The EWS/NOR1 fusion protein (arising from chromosomal translocation in extraskeletal myxoid chondrosarcoma) gains a novel activity affecting pre-mRNA splicing: it complements loss of function of yeast splicing factor Snu23p, causes increased usage of distal 5'-splice sites in mammalian cells, and interacts with the human splicing protein U1C—activities not possessed by EWS or NOR1 alone.","method":"Functional complementation screening in yeast, pre-mRNA splicing assay in mammalian cells, co-immunoprecipitation with U1C splicing protein","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1-2 — multiple orthogonal methods (yeast complementation, mammalian splicing assay, Co-IP), single lab with strong mechanistic rigor","pmids":["11673470"],"is_preprint":false},{"year":1999,"finding":"In extraskeletal myxoid chondrosarcoma with t(9;17)(q22;q11), the NR4A3 (CHN/TEC) gene fuses with RBP56 (TAF15) to generate a chimeric RBP56/CHN oncogenic fusion, demonstrating that the N-terminal transactivation domains of EWS and RBP56 are pathogenetically equivalent when fused to NR4A3.","method":"Molecular cloning, RT-PCR, chromosomal translocation breakpoint analysis","journal":"Oncogene","confidence":"High","confidence_rationale":"Tier 2 — molecularly characterized fusion gene confirmed in patient samples, replicated across EMC literature","pmids":["10602519"],"is_preprint":false},{"year":2010,"finding":"NR4A3 (Nor-1) in endothelial cells is rapidly induced by inflammatory stimuli through NF-κB-dependent transactivation of the NOR1 promoter; NOR1 induces VCAM-1 promoter activity by directly binding to a canonical NR4A response element in the VCAM-1 promoter (confirmed by ChIP and transient transfection); NOR1 deficiency in apoE-/- mice reduces atherosclerosis by decreasing macrophage content.","method":"ChIP assay, transient transfection with VCAM-1 promoter-reporter constructs, NOR1-deficient mouse atherosclerosis model, monocyte adhesion functional assay","journal":"Circulation research","confidence":"High","confidence_rationale":"Tier 1-2 — ChIP confirms direct promoter binding, functional in vivo validation in knockout mice","pmids":["20558821"],"is_preprint":false},{"year":2010,"finding":"NR4A3 (Nor-1) translocates from the nucleus to mitochondria in thymocytes undergoing apoptosis; this translocation requires phosphorylation by PKC (both classical and novel isoforms); Nor-1 associates with Bcl-2 in the mitochondria, inducing a conformational change that exposes the Bcl-2 BH3 domain.","method":"PKC inhibitor pharmacology, phosphorylation analysis, subcellular fractionation/translocation assay, Bcl-2 BH3 conformation assay in thymocytes","journal":"European journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2 — localization with functional consequence and mechanistic follow-up, single lab","pmids":["20411565"],"is_preprint":false},{"year":2014,"finding":"Nkx6.1 induces expression of Nr4a3 (and Nr4a1) in pancreatic islets; Nr4a3 is both necessary and sufficient for Nkx6.1-mediated β-cell proliferation; Nr4a3 increases expression of cell cycle inducers E2F1 and cyclin E1, and induces components of the anaphase-promoting complex (including UBE2C), leading to degradation of the cell cycle inhibitor p21.","method":"Adenoviral overexpression, siRNA knockdown, global Nr4a1 knockout mice, gene expression analysis","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 — necessity and sufficiency experiments with defined molecular pathway, multiple methods","pmids":["24706823"],"is_preprint":false},{"year":2008,"finding":"Retroviral overexpression of NR4A3 (NOR1) in 3T3-L1 or 3T3-F442A preadipocytes potently inhibits adipogenesis in a manner that cannot be rescued by PPARγ overexpression or activation; NR4A3 inhibits mitotic clonal expansion of preadipocytes; NOR1 (and family members Nur77 and Nurr1) upregulate gap-junction protein Gja1 and Tll1 as downstream mediators.","method":"Retroviral transduction, adipogenesis assays, transcriptional profiling, retroviral expression of target genes","journal":"Molecular endocrinology (Baltimore, Md.)","confidence":"Medium","confidence_rationale":"Tier 2 — gain-of-function with defined cellular phenotype and target gene identification, single lab","pmids":["18945812"],"is_preprint":false},{"year":2011,"finding":"NR4A3 is a direct transcriptional target of RUNX1; downregulation of NR4A3 in RUNX1-mutated hematopoietic progenitors increases clonogenic potential; restoration of NR4A3 expression partially reduces the clonogenic potential of patient progenitors from familial platelet disorder/AML pedigrees.","method":"ChIP demonstrating RUNX1 binding to NR4A3 promoter, lentiviral NR4A3 restoration in patient-derived CD34+ progenitors, clonogenic assays","journal":"Blood","confidence":"High","confidence_rationale":"Tier 1-2 — direct ChIP evidence for RUNX1→NR4A3 regulation plus functional rescue in patient cells","pmids":["21725049"],"is_preprint":false},{"year":2018,"finding":"NR4A3 is a direct transcriptional target of p53: p53 binds the promoter of NR4A3 and induces its transcription; NR4A3 overexpression promotes apoptosis by augmenting pro-apoptotic genes PUMA and Bax; NR4A3 physically interacts with anti-apoptotic Bcl-2 protein, sequestering it from inhibiting apoptosis.","method":"ChIP assay for p53 binding to NR4A3 promoter, luciferase reporter assay, Co-immunoprecipitation (NR4A3-Bcl-2 interaction), overexpression/knockdown with apoptosis readout","journal":"Oncogene","confidence":"High","confidence_rationale":"Tier 1-2 — multiple orthogonal methods including ChIP, reporter assay, and Co-IP, single lab","pmids":["30455429"],"is_preprint":false},{"year":2018,"finding":"NR4A1 and NR4A3 (NR4A1/3) restrict HSC proliferation by directly binding to a hematopoietic-specific Cebpa enhancer to activate C/EBPα transcription; NR4A1/3 also occupy regulatory regions of NF-κB-regulated inflammatory cytokines, antagonizing NF-κB signaling; conditional knockout of NR4A1/3 in HSCs causes loss of quiescence, accumulation of oxidative stress, DNA damage, and upregulation of cell cycle and inflammation programs.","method":"Conditional double knockout mouse model, ChIP-seq/genomic occupancy studies, molecular profiling of HSCs, NF-κB signaling analysis","journal":"Blood","confidence":"High","confidence_rationale":"Tier 1-2 — direct genomic binding evidence plus conditional KO with defined HSC phenotype","pmids":["29343483"],"is_preprint":false},{"year":2016,"finding":"NR4A3 (NOR-1) is essential for migration of CD103+ dendritic cells to lymph nodes; this defect is cell-intrinsic; NR4A3 deficiency causes marked loss of surface CCR7 expression specifically on CD103+ DCs (not T cells); NR4A3 maintains FOXO1 protein levels in CD103+ DCs through an AKT-dependent mechanism, and FOXO1 regulates CCR7 expression; NR4A3 is also required for homeostatic mitochondrial function in CD103+ DCs.","method":"Nr4a3-deficient mouse model, mixed bone marrow chimera (cell-intrinsic proof), flow cytometry for CCR7/FOXO1, AKT pathway inhibitor studies","journal":"The Journal of clinical investigation","confidence":"High","confidence_rationale":"Tier 2 — cell-intrinsic KO with defined migration and molecular phenotype, multiple orthogonal approaches","pmids":["27820700"],"is_preprint":false},{"year":2019,"finding":"NR4A3 is required for differentiation of monocytes into monocyte-derived dendritic cells (MoDCs) but not other DC types; Nr4a3-/- mice show severely impaired generation of DC-SIGN+ MoDCs in response to LPS, resulting in inability to mount optimal CD8+ T cell responses to gram-negative bacteria; transcriptomics shows NR4A3 skews monocyte fate toward MoDCs over macrophages and enables acquisition of migratory characteristics.","method":"Nr4a3-/- mouse model, flow cytometry, transcriptomic analysis, in vivo bacterial infection challenge","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 — genetic KO with defined differentiation phenotype, transcriptomic mechanism, and functional immune readout","pmids":["31285338"],"is_preprint":false},{"year":2020,"finding":"NR4A3 deficiency in CD8+ T cells leads to preferential differentiation into memory precursor and central memory cells with increased cytokine production; NR4A3 deficiency early programs memory transcriptional programs and increases chromatin accessibility at bZIP transcription factor motifs, affecting Fos/Jun target gene transcription.","method":"NR4A3-deficient murine CD8+ T cells, ATAC-seq for chromatin accessibility, transcriptional profiling, cytokine production assays","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 — KO with epigenomic and transcriptomic mechanism, multiple orthogonal methods","pmids":["32913051"],"is_preprint":false},{"year":2022,"finding":"Dual knockout of PRDM1 and NR4A3 in CAR T cells skews phenotypes away from TIM-3+CD8+ toward TCF1+CD8+, countering exhaustion and improving antitumor responses; NR4A3 is identified as part of an NFAT-driven T cell dysfunction program that is upregulated as negative epigenetic feedback when PRDM1 is deleted.","method":"CRISPR knockout (single and dual) in CAR T cells, scRNA-seq, in vivo tumor models","journal":"Science translational medicine","confidence":"High","confidence_rationale":"Tier 2 — genetic epistasis with defined phenotypic readout, scRNA-seq mechanistic support, in vivo validation","pmids":["36350986"],"is_preprint":false},{"year":2015,"finding":"NR4A3 (NOR1) physically interacts with PARP-1 (confirmed by co-immunoprecipitation); NOR1 overexpression enhances PARP-1 activity and promotes cardiac hypertrophy; a NOR1 mutant (C293Y) lacking PARP-1 binding activity fails to induce hypertrophy; PARP-1 inhibition or siRNA blocks NOR1-driven hypertrophic effects.","method":"Co-immunoprecipitation (NOR1-PARP-1), NOR1 overexpression/knockdown in neonatal rat cardiomyocytes, C293Y mutant analysis, PARP-1 activity assay, hypertrophy markers","journal":"British journal of pharmacology","confidence":"High","confidence_rationale":"Tier 1-2 — Co-IP plus mutagenesis and pharmacological validation, single lab with multiple orthogonal approaches","pmids":["25625556"],"is_preprint":false},{"year":2019,"finding":"NR4A3 (Nor1) negatively regulates β-cell mass: Nor1 knockout mice display increased β-cell mass and improved glucose tolerance; Nor1 expression is induced by pro-inflammatory cytokines and elevated glucose; Nor1 overexpression in INS and human islet cells causes apoptosis, while siRNA-mediated Nor1 knockdown prevents cytokine-induced β-cell death.","method":"Nor1 knockout mouse histological analysis, lentiviral overexpression, siRNA knockdown in INS cells and human islets, apoptosis assays","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 — genetic KO plus gain/loss-of-function with defined β-cell phenotype, multiple methods","pmids":["30696767"],"is_preprint":false},{"year":2017,"finding":"NR4A3 (NOR-1) directly regulates vitronectin (VTN) expression in human vascular smooth muscle cells by binding to an NBRE(-202/-195) site in the VTN promoter; NOR-1-driven VTN secretion promotes VSMC migration; this was confirmed by EMSA, ChIP, deletion and site-directed mutagenesis studies.","method":"Lentiviral NOR-1 overexpression/silencing, EMSA, ChIP, promoter deletion/mutagenesis with reporter assays, cell migration assay with anti-VTN blocking antibody","journal":"FASEB journal","confidence":"High","confidence_rationale":"Tier 1 — direct DNA-binding confirmed by EMSA and ChIP with mutagenesis, functional consequence demonstrated","pmids":["28666984"],"is_preprint":false},{"year":2016,"finding":"NR4A3 (NOR-1) expression is induced by exercise via calcium/calcineurin signaling in skeletal muscle; transgenic Nor-1 expression in skeletal muscle induces muscle hypertrophy, vascularization, and increased autophagy (elevated LC3A-II, autophagy protein 5 and 12, decreased p62, decreased mTORC1 activity).","method":"Transgenic Nor-1 mouse model, calcineurin inhibitor pharmacology, autophagy marker analysis (LC3A-GFP-RFP chimera), exercise studies","journal":"Molecular endocrinology (Baltimore, Md.)","confidence":"Medium","confidence_rationale":"Tier 2 — transgenic mouse model with defined metabolic phenotype and pathway analysis, single lab","pmids":["27144290"],"is_preprint":false},{"year":2016,"finding":"NR4A3 (NOR-1) regulates the small muscle protein X-linked (SMPX) in human vascular smooth muscle cells and skeletal muscle cells by binding to a non-consensus NBRE site in the human SMPX promoter; NOR-1 silencing prevents SMPX expression and differentiation of human skeletal muscle myoblasts to myotubes.","method":"Lentiviral NOR-1 overexpression/silencing, transcriptional reporter assays, EMSA (DNA-protein binding), NOR-1 siRNA knockdown in HSMM differentiation","journal":"Scientific reports","confidence":"Medium","confidence_rationale":"Tier 2 — DNA-protein binding and reporter assays with loss-of-function, single lab","pmids":["27181368"],"is_preprint":false},{"year":2013,"finding":"6-Mercaptopurine (6-MP) activates NR4A3 (NOR-1) and enhances glucose transport activity in L6 skeletal muscle cells via increased GLUT4 translocation in an NR4A3-dependent manner; 6-MP also increases phospho-AS160 through NR4A3-independent mechanisms.","method":"NR4A3 overexpression/knockdown in L6 cells, glucose transport assay, GLUT4 translocation assay, 6-MP pharmacology","journal":"American journal of physiology. Endocrinology and metabolism","confidence":"Medium","confidence_rationale":"Tier 2 — gain/loss-of-function with defined metabolic phenotype, single lab","pmids":["24022864"],"is_preprint":false},{"year":2019,"finding":"NR4A3 overexpression in mouse salivary gland cells increases expression of known NR4A3 target genes and stimulates cell proliferation; recurrent t(4;9)(q13;q31) chromosomal rearrangements in acinic cell carcinoma translocate active SCPP enhancer regions upstream of NR4A3, driving its ectopic overexpression (enhancer hijacking); active chromatin regions and gene expression signatures in AciCCs correlate with NR4A3 transcription factor binding motifs.","method":"Whole genome sequencing, RNA-seq, ATAC-seq/chromatin profiling, NR4A3 overexpression in salivary gland cells with proliferation assay","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 — multi-omic evidence plus functional overexpression, strong mechanistic support","pmids":["30664630"],"is_preprint":false},{"year":2015,"finding":"NR4A3 (Nor1) and NR4A1 (Nur77) increase thrombomodulin expression in endothelial cells through distinct mechanisms: Nur77 increases thrombomodulin mRNA stability (not promoter activity), whereas Nor1 enhances thrombomodulin expression primarily through induction of Krüppel-like factors 2 and 4 (KLF2/4); both receptors increase protein C activity and inhibit prothrombotic effects.","method":"Adenovirus-mediated transduction of Nur77 and Nor1 cDNAs, mRNA stability assays, promoter activity assays, KLF2/4 expression analysis, protein C activity assay, Nur77-deficient mouse thrombosis model","journal":"Arteriosclerosis, thrombosis, and vascular biology","confidence":"Medium","confidence_rationale":"Tier 2 — distinct mechanistic pathways demonstrated for Nor1, single lab with multiple approaches","pmids":["26634653"],"is_preprint":false},{"year":2024,"finding":"NR4A3 promotes vascular calcification via histone lactylation: NR4A3 directly binds to promoters of glycolysis genes ALDOA and PFKL to drive their transcription, thereby enhancing glycolysis and lactate production; elevated lactate promotes histone lactylation, which in turn activates transcription of Phospho1 (PHOSPHO1), promoting calcium deposition; NR4A3 deficiency inhibits this cascade and reduces calcification.","method":"NR4A3-/- mouse models of medial arterial calcification, RNA-seq, CUT&TAG chromatin occupancy analysis, glycolysis/lactate assays, Phospho1 pharmacological inhibition and overexpression","journal":"Circulation research","confidence":"High","confidence_rationale":"Tier 1-2 — direct genomic binding evidence (CUT&TAG) plus multi-step mechanistic validation in KO mice and cell models","pmids":["38629274"],"is_preprint":false},{"year":2016,"finding":"Muscle contraction induces acute hydroxymethylation followed by demethylation of the NR4A3 promoter: electrical pulse stimulation causes early hydroxymethylation at the NR4A3 promoter (highest immediately post-EPS), followed by demethylation at 60 min and re-methylation at 120 min, accompanying transcriptional induction of NR4A3.","method":"Targeted bisulfite sequencing, hydroxymethylcytosine analysis, electrical pulse stimulation of C2C12 myotubes, acute exercise study in humans","journal":"Frontiers in endocrinology","confidence":"Medium","confidence_rationale":"Tier 2 — direct epigenetic mapping at NR4A3 promoter with temporal resolution, single lab","pmids":["28066330"],"is_preprint":false},{"year":2017,"finding":"NR4A3 knockdown in bone marrow-derived dendritic cells suppresses TLR-mediated upregulation of CD80, CD86, IL-10, IL-6, and IL-12; NR4A3 knockdown decreases expression of IKKβ, IRF4, and IRF8; IKKβ mediates IL-10 and IL-6 induction while IRF4/IRF8 mediate IL-12 induction downstream of NR4A3.","method":"siRNA knockdown in bone marrow-derived DCs, cytokine and surface marker expression analysis, secondary siRNA knockdown of IKKβ/IRF4/IRF8","journal":"Journal of immunology (Baltimore, Md. : 1950)","confidence":"Medium","confidence_rationale":"Tier 2 — loss-of-function with defined molecular pathway via epistasis (secondary siRNA), single lab","pmids":["28893954"],"is_preprint":false},{"year":2018,"finding":"NR4A3 knockdown in BeWo trophoblast cells increases FSK-induced cell fusion and expression of syncytialization markers (CGB, syncytin2), indicating that cAMP-PKA-upregulated NR4A3 acts as a negative regulator of syncytialization; NR4A3 counterbalances the positive regulator STAT5B in controlling the degree of trophoblast cell fusion.","method":"siRNA knockdown of NR4A3 in BeWo cells, microarray analysis, syncytialization assay (cell fusion), RT-PCR for syncytialization markers","journal":"Journal of cellular biochemistry","confidence":"Medium","confidence_rationale":"Tier 2 — loss-of-function with defined cellular phenotype and molecular markers, single lab","pmids":["29377304"],"is_preprint":false},{"year":2004,"finding":"NR4A3 (NOR1) physically interacts with the homeodomain transcription factor SIX3 and stimulates its transcriptional activity; the SIX3 holoprosencephaly mutation p.R257P abolishes the interaction with NOR1 in vivo, while p.L226V does not alter this interaction, demonstrating that different HPE2 SIX3 mutations affect distinct signaling pathways.","method":"GST fusion protein pull-down assays, transient co-transfection with expression and reporter vectors in Neuro-2a cells","journal":"Human mutation","confidence":"Medium","confidence_rationale":"Tier 2 — direct protein-protein interaction with mutagenesis, single lab","pmids":["15523651"],"is_preprint":false},{"year":2019,"finding":"NR4A3 plays a pro-inflammatory role in osteoarthritis chondrocytes by enhancing IL-1β-stimulated expression of matrix-degrading enzymes (MMP-3, MMP-9, iNOS, COX-2) and enhancing NF-κB activation; NR4A3 overexpression also enhances EBSS-induced chondrocyte apoptosis.","method":"Lentiviral overexpression and siRNA knockdown in chondrocytes, NF-κB signaling analysis, MMP/iNOS/COX-2 expression, apoptosis assay","journal":"Journal of cellular and molecular medicine","confidence":"Medium","confidence_rationale":"Tier 2 — gain/loss-of-function with defined pro-inflammatory pathway, single lab","pmids":["31701670"],"is_preprint":false},{"year":2020,"finding":"miR-106b-5p targets the 3' UTR of NR4A3 mRNA and negatively regulates NR4A3 expression, thereby inducing Treg/Th17 immune imbalance in immune thrombocytopenic purpura; NR4A3 regulates Treg differentiation via Foxp3; sh-NR4A3 decreases Foxp3 and TGF-β expression.","method":"Dual-luciferase reporter assay (miR-106b-5p/NR4A3 3'UTR), qRT-PCR, western blot, sh-NR4A3 knockdown, in vivo silencing of miR-106b-5p","journal":"Cell cycle (Georgetown, Tex.)","confidence":"Medium","confidence_rationale":"Tier 2 — direct 3'UTR targeting confirmed by luciferase assay with in vivo validation, single lab","pmids":["32323598"],"is_preprint":false},{"year":2024,"finding":"NR4A3 protects against diabetes-induced atrial remodeling by preserving mitochondrial energy metabolism and reducing oxidative stress; NR4A3 maintains transcriptional expression of Sdha (succinate dehydrogenase subunit A); NR4A3 deficiency exacerbates atrial fibrosis and increases AF susceptibility, while AAV9-mediated NR4A3 overexpression alleviates atrial remodeling in db/db mice.","method":"Nr4a3-/- mouse model, AAV9-Nr4a3 overexpression in db/db mice, RNA-seq, metabolomics, electrophysiological analysis, histological analysis","journal":"EBioMedicine","confidence":"Medium","confidence_rationale":"Tier 2 — bidirectional genetic manipulation with defined molecular mechanism (Sdha regulation), single lab","pmids":["39098108"],"is_preprint":false},{"year":2016,"finding":"NOR1 (NR4A3) cooperates with a FOXA1-HDAC2 complex to repress Slug transcription, inhibiting epithelial-mesenchymal transition in nasopharyngeal carcinoma; FOXA1 and HDAC2 bind the slug promoter and directly repress its transcription.","method":"Data mining of gene expression profiles, ectopic expression, RNA interference, chromatin-related functional assays","journal":"Oncotarget","confidence":"Medium","confidence_rationale":"Tier 3 — mechanistic cooperation shown but primarily based on ectopic expression and RNAi without direct binding confirmation for NOR1 specifically","pmids":["26934447"],"is_preprint":false},{"year":2022,"finding":"FTO (fat mass and obesity-associated protein) demethylates NR4A3 mRNA (m6A modification); FTO knockdown increases methylation of NR4A3 mRNA; DHA (dihydroartemisinin) suppresses AngII-induced VSMC proliferation and inflammation by inhibiting the FTO/NR4A3 axis.","method":"m6A-RIP assay (MeRIP), FTO knockdown/overexpression with mutant FTO control, CCK-8 proliferation assay, immunofluorescence","journal":"Inflammation research","confidence":"Medium","confidence_rationale":"Tier 2 — direct m6A modification on NR4A3 mRNA demonstrated by MeRIP with mutant control, single lab","pmids":["35059772"],"is_preprint":false}],"current_model":"NR4A3 (NOR-1) is a ligand-independent orphan nuclear receptor that functions as a transcription factor by binding NBRE and NurRE response elements to regulate target genes (VCAM-1, VTN, SMPX, ALDOA, PFKL, Cebpa, thrombomodulin via KLF2/4, Sdha) involved in inflammation, proliferation, apoptosis, and metabolism; it undergoes PKC-dependent nuclear-to-mitochondrial translocation where it interacts with Bcl-2 to promote apoptosis, physically associates with PARP-1 and SIX3, is directly transcriptionally induced by p53 and RUNX1, is activated by prostaglandin A2 through its LBD, and its mRNA is subject to FTO-mediated m6A modification; loss of NR4A3 (alone or with NR4A1) causes AML in mice through failure to maintain HSC quiescence and C/EBPα-driven antiproliferative programs, while in immunity NR4A3 is required for CD103+ DC migration via FOXO1/CCR7 and for monocyte-to-MoDC differentiation, and in T cells it programs CD8+ T cell fate toward effector over memory by driving exhaustion-associated transcriptional programs."},"narrative":{"teleology":[{"year":1999,"claim":"Identification of NR4A3 as a recurrent fusion partner in extraskeletal myxoid chondrosarcoma established that its transcriptional domains are oncogenically relevant when dysregulated, motivating study of its normal transcriptional function.","evidence":"Molecular cloning and breakpoint analysis of t(9;17) and t(4;9) translocations in EMC patient tumors","pmids":["10602519"],"confidence":"High","gaps":["Mechanism by which EWS-NR4A3 or TAF15-NR4A3 fusions drive sarcomagenesis not fully defined","Whether wild-type NR4A3 has any role in chondrocyte biology was unknown"]},{"year":2000,"claim":"Demonstration that NR4A3 binds NBRE promoter elements and activates steroidogenic gene transcription via PKA/PKC cascades established it as a functional transcription factor responsive to hormonal signaling.","evidence":"Reporter assays with NBRE sequences and PKA/PKC inhibitor pharmacology in adrenal fasciculata cells","pmids":["10875239"],"confidence":"Medium","gaps":["Endogenous chromatin occupancy not confirmed","Whether NR4A3 has ligand-independent versus ligand-dependent activity was still debated"]},{"year":2001,"claim":"The EWS/NOR1 fusion was shown to gain a neomorphic splicing activity by interacting with U1C, demonstrating that the fusion creates functions absent from either partner alone.","evidence":"Yeast splicing complementation, mammalian splice-site assay, and co-immunoprecipitation with U1C","pmids":["11673470"],"confidence":"High","gaps":["Relevance of splicing disruption to EMC tumorigenesis not established","Whether wild-type NR4A3 has any role in RNA processing is unknown"]},{"year":2005,"claim":"Prostaglandin A2 was identified as a ligand that activates NR4A3 through direct binding to its LBD, partially resolving whether this 'orphan' receptor has physiological ligands.","evidence":"GAL4-LBD reporter system and direct LBD binding assay","pmids":["16141523"],"confidence":"Medium","gaps":["Physiological relevance of PGA2 as an endogenous NR4A3 ligand in vivo not confirmed","Structural basis of LBD-PGA2 interaction not resolved"]},{"year":2007,"claim":"Double knockout of NR4A3 and NR4A1 caused rapidly lethal AML with HSC expansion and defective extrinsic apoptosis, establishing NR4A3 as a bona fide tumor suppressor in myeloid leukemogenesis.","evidence":"Nr4a1/Nr4a3 double knockout mice with AML phenotype, validated against human AML samples","pmids":["17515897"],"confidence":"High","gaps":["Individual contribution of NR4A3 versus NR4A1 to leukemia suppression not separated","Direct transcriptional targets mediating tumor suppression were unknown at this point"]},{"year":2010,"claim":"Two parallel discoveries defined NR4A3's mechanism in vascular inflammation and apoptosis: ChIP demonstrated direct VCAM-1 promoter binding in endothelial cells, while subcellular fractionation showed PKC-dependent nuclear-to-mitochondrial translocation where NR4A3 engages Bcl-2 to expose its BH3 domain.","evidence":"ChIP and NOR1-deficient apoE−/− atherosclerosis model (VCAM-1); PKC inhibitor pharmacology and Bcl-2 BH3 conformation assay in thymocytes (apoptosis)","pmids":["20558821","20411565"],"confidence":"High","gaps":["Whether mitochondrial translocation and transcriptional function are coordinated or independent programs","Structural details of NR4A3-Bcl-2 interaction not resolved"]},{"year":2011,"claim":"Identification of NR4A3 as a direct RUNX1 transcriptional target linked familial platelet disorder/AML predisposition to NR4A3 downregulation, explaining how RUNX1 mutations expand myeloid progenitors.","evidence":"ChIP showing RUNX1 binding to NR4A3 promoter; lentiviral NR4A3 restoration partially rescued clonogenicity in FPD/AML patient CD34+ cells","pmids":["21725049"],"confidence":"High","gaps":["Whether NR4A3 restoration alone is sufficient to prevent leukemic transformation in RUNX1-mutant settings","Other RUNX1 targets may contribute in parallel"]},{"year":2014,"claim":"NR4A3 was shown to be necessary and sufficient for Nkx6.1-driven β-cell proliferation, operating through E2F1/cyclin E1 upregulation and APC-mediated p21 degradation, revealing a cell cycle–promoting role distinct from its tumor-suppressive function in hematopoiesis.","evidence":"Adenoviral overexpression and siRNA knockdown in islets, global Nr4a1 KO mice","pmids":["24706823"],"confidence":"High","gaps":["Whether NR4A3 directly binds E2F1 or cyclin E1 promoters not shown","Context-dependent switch between pro-proliferative and anti-proliferative roles not mechanistically explained"]},{"year":2015,"claim":"Discovery of a physical NR4A3–PARP-1 interaction that drives cardiac hypertrophy, with the C293Y mutation abolishing this interaction and hypertrophic response, established a non-transcriptional effector partnership for NR4A3.","evidence":"Co-immunoprecipitation, C293Y mutant analysis, PARP-1 activity assay, and hypertrophy markers in neonatal rat cardiomyocytes","pmids":["25625556"],"confidence":"High","gaps":["Whether PARP-1 activation requires NR4A3 transcriptional activity or is purely protein-protein","In vivo cardiac phenotype of NR4A3 loss not reported"]},{"year":2016,"claim":"Multiple studies established NR4A3's immune roles: it is essential for CD103+ DC migration via maintenance of FOXO1/CCR7, and it regulates TLR-mediated DC activation through IKKβ and IRF4/IRF8.","evidence":"Nr4a3-deficient mice with mixed bone marrow chimeras (cell-intrinsic DC migration defect); siRNA in BMDCs with epistatic knockdown of IKKβ/IRF4/IRF8","pmids":["27820700","28893954"],"confidence":"High","gaps":["Direct transcriptional targets of NR4A3 that maintain FOXO1 protein levels not identified","Whether NR4A3 directly binds IKKβ or IRF promoters unknown"]},{"year":2017,"claim":"Direct NBRE-dependent regulation of vitronectin by NR4A3 in vascular smooth muscle cells was rigorously confirmed by EMSA, ChIP, and site-directed mutagenesis, linking NR4A3 to VSMC migration.","evidence":"EMSA, ChIP, promoter deletion/mutagenesis with reporter assays, migration assay with anti-VTN blocking antibody in human VSMCs","pmids":["28666984"],"confidence":"High","gaps":["In vivo relevance to neointimal formation or vascular remodeling not demonstrated"]},{"year":2018,"claim":"Two key advances resolved NR4A3's upstream regulation by p53 (direct promoter binding inducing apoptosis via PUMA/Bax) and its direct role in HSC quiescence through binding the Cebpa enhancer and antagonizing NF-κB at inflammatory gene loci.","evidence":"ChIP for p53 at NR4A3 promoter and NR4A3-Bcl-2 co-IP (p53 axis); ChIP-seq and conditional double KO in HSCs (Cebpa/NF-κB axis)","pmids":["30455429","29343483"],"confidence":"High","gaps":["Whether p53-NR4A3 axis operates in leukemia suppression in vivo","Relative contributions of Cebpa activation versus NF-κB antagonism to HSC quiescence not quantified"]},{"year":2019,"claim":"NR4A3 was shown to direct monocyte-to-MoDC differentiation fate and to negatively regulate β-cell mass by inducing apoptosis under inflammatory conditions, illustrating its context-dependent pro-apoptotic versus differentiation functions.","evidence":"Nr4a3−/− mice with LPS challenge and bacterial infection (MoDC); Nr4a3 KO mice with β-cell mass quantification, overexpression/knockdown in INS cells and human islets","pmids":["31285338","30696767"],"confidence":"High","gaps":["Direct transcriptional targets driving MoDC versus macrophage fate choice not identified","Whether β-cell apoptotic function involves mitochondrial translocation not tested"]},{"year":2020,"claim":"NR4A3 deficiency in CD8+ T cells revealed that NR4A3 normally programs effector differentiation at the expense of memory: its loss increased chromatin accessibility at bZIP/AP-1 motifs and enhanced memory precursor generation.","evidence":"NR4A3-deficient murine CD8+ T cells with ATAC-seq, transcriptional profiling, and cytokine assays","pmids":["32913051"],"confidence":"High","gaps":["Whether NR4A3 directly binds and represses memory-associated loci or acts indirectly","Interaction with NR4A1 in T cell fate decisions not dissected"]},{"year":2022,"claim":"Dual PRDM1/NR4A3 CRISPR knockout in CAR T cells reduced exhaustion and improved antitumor efficacy, positioning NR4A3 as a targetable node in NFAT-driven T cell dysfunction.","evidence":"CRISPR KO in CAR T cells, scRNA-seq, in vivo tumor models","pmids":["36350986"],"confidence":"High","gaps":["Whether NR4A3 deletion alone is sufficient for durable CAR T improvement","Mechanism of NFAT-NR4A3 transcriptional feedback not fully defined"]},{"year":2024,"claim":"NR4A3 was found to drive vascular calcification through a metabolic-epigenetic cascade: direct binding to ALDOA/PFKL promoters enhances glycolysis and lactate production, which promotes histone lactylation and downstream PHOSPHO1 activation.","evidence":"CUT&TAG chromatin occupancy, NR4A3−/− mice with medial arterial calcification models, glycolysis/lactate assays, RNA-seq","pmids":["38629274"],"confidence":"High","gaps":["Whether this glycolysis–lactylation axis operates in other NR4A3-expressing tissues","Structural basis for NR4A3 selectivity at ALDOA versus other glycolytic gene promoters unknown"]},{"year":null,"claim":"A unifying mechanistic framework explaining how NR4A3 switches between pro-proliferative (β-cells, salivary gland), anti-proliferative (HSCs), and pro-apoptotic (thymocytes, cancer) outputs in different cellular contexts remains undefined.","evidence":"","pmids":[],"confidence":"Low","gaps":["No structural model of full-length NR4A3 exists","Endogenous physiological ligand(s) remain debated","How post-translational modifications (PKC phosphorylation, m6A on mRNA) are integrated to determine nuclear versus mitochondrial function is unresolved"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0003677","term_label":"DNA binding","supporting_discovery_ids":[1,5,11,18,20,24]},{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[1,5,7,8,11,18,20,22,24]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[6,10,15,29]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[1,5,6,11,18,24]},{"term_id":"GO:0005739","term_label":"mitochondrion","supporting_discovery_ids":[6,10]}],"pathway":[{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[1,5,7,11,18,20,22,24]},{"term_id":"R-HSA-5357801","term_label":"Programmed Cell Death","supporting_discovery_ids":[0,6,10,17]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[12,13,14,15,26,30]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[0,9,11,22]},{"term_id":"R-HSA-1430728","term_label":"Metabolism","supporting_discovery_ids":[21,24]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[2,5,29]}],"complexes":[],"partners":["BCL2","PARP1","SIX3","NR4A1","FOXO1","KLF2","KLF4","FOXA1"],"other_free_text":[]},"mechanistic_narrative":"NR4A3 (NOR-1) is an orphan nuclear receptor that functions as a ligand-independent transcription factor governing cell fate decisions across hematopoietic, vascular, metabolic, and immune lineages. It binds NBRE response elements in target gene promoters—including VCAM-1, VTN, SMPX, ALDOA, PFKL, and Cebpa—to regulate inflammation, proliferation, and metabolic programs [PMID:20558821, PMID:28666984, PMID:29343483, PMID:38629274]. Beyond its nuclear transcriptional role, NR4A3 undergoes PKC-dependent translocation to mitochondria where it interacts with Bcl-2 to expose its BH3 domain and promote apoptosis, and it is itself transcriptionally regulated by p53, RUNX1, and NF-κB [PMID:20411565, PMID:30455429, PMID:21725049]. Combined loss of NR4A3 and NR4A1 causes acute myeloid leukemia in mice through failure to maintain HSC quiescence and C/EBPα expression, while in the immune system NR4A3 is required for CD103+ dendritic cell migration via FOXO1/CCR7, monocyte-to-MoDC differentiation, and programming of CD8+ T cell effector versus memory fate [PMID:17515897, PMID:27820700, PMID:31285338, PMID:32913051]."},"prefetch_data":{"uniprot":{"accession":"Q92570","full_name":"Nuclear receptor subfamily 4 group A member 3","aliases":["Mitogen-induced nuclear orphan receptor","Neuron-derived orphan receptor 1","Nuclear hormone receptor NOR-1","Translocated in extraskeletal chondrosarcoma"],"length_aa":626,"mass_kda":68.2,"function":"Transcriptional activator that binds to regulatory elements in promoter regions in a cell- and response element (target)-specific manner. Induces gene expression by binding as monomers to the NR4A1 response element (NBRE) 5'-AAAAGGTCA-3' site and as homodimers to the Nur response element (NurRE) site in the promoter of their regulated target genes (By similarity). Plays a role in the regulation of proliferation, survival and differentiation of many different cell types and also in metabolism and inflammation. Mediates proliferation of vascular smooth muscle, myeloid progenitor cell and type B pancreatic cells; promotes mitogen-induced vascular smooth muscle cell proliferation through transactivation of SKP2 promoter by binding a NBRE site (By similarity). Upon PDGF stimulation, stimulates vascular smooth muscle cell proliferation by regulating CCND1 and CCND2 expression. In islets, induces type B pancreatic cell proliferation through up-regulation of genes that activate cell cycle, as well as genes that cause degradation of the CDKN1A (By similarity). Negatively regulates myeloid progenitor cell proliferation by repressing RUNX1 in a NBRE site-independent manner. During inner ear, plays a role as a key mediator of the proliferative growth phase of semicircular canal development (By similarity). Also mediates survival of neuron and smooth muscle cells; mediates CREB-induced neuronal survival, and during hippocampus development, plays a critical role in pyramidal cell survival and axonal guidance. Is required for S phase entry of the cell cycle and survival of smooth muscle cells by inducing CCND1, resulting in RB1 phosphorylation. Binds to NBRE motif in CCND1 promoter, resulting in the activation of the promoter and CCND1 transcription (By similarity). Also plays a role in inflammation; upon TNF stimulation, mediates monocyte adhesion by inducing the expression of VCAM1 and ICAM1 by binding to the NBRE consensus site (By similarity) (PubMed:20558821). In mast cells activated by Fc-epsilon receptor cross-linking, promotes the synthesis and release of cytokines but impairs events leading to degranulation (By similarity). Also plays a role in metabolism; by modulating feeding behavior; and by playing a role in energy balance by inhibiting the glucocorticoid-induced orexigenic neuropeptides AGRP expression, at least in part by forming a complex with activated NR3C1 on the AGRP- glucocorticoid response element (GRE), and thus weakening the DNA binding activity of NR3C1. Upon catecholamines stimulation, regulates gene expression that controls oxidative metabolism in skeletal muscle (By similarity). Plays a role in glucose transport by regulating translocation of the SLC2A4 glucose transporter to the cell surface (PubMed:24022864). Finally, during gastrulation plays a crucial role in the formation of anterior mesoderm by controlling cell migration. Inhibits adipogenesis (By similarity). Also participates in cardiac hypertrophy by activating PARP1 (By similarity)","subcellular_location":"Nucleus","url":"https://www.uniprot.org/uniprotkb/Q92570/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/NR4A3","classification":"Not Classified","n_dependent_lines":0,"n_total_lines":1208,"dependency_fraction":0.0},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/NR4A3","total_profiled":1310},"omim":[{"mim_id":"612237","title":"CHONDROSARCOMA, EXTRASKELETAL MYXOID","url":"https://www.omim.org/entry/612237"},{"mim_id":"604204","title":"SYNTAXIN 17; STX17","url":"https://www.omim.org/entry/604204"},{"mim_id":"603714","title":"SIX HOMEOBOX 3; SIX3","url":"https://www.omim.org/entry/603714"},{"mim_id":"602563","title":"NK6 HOMEOBOX 1; NKX6-1","url":"https://www.omim.org/entry/602563"},{"mim_id":"602498","title":"TRAFFICKING FROM ER TO GOLGI REGULATOR; TFG","url":"https://www.omim.org/entry/602498"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in many","driving_tissues":[],"url":"https://www.proteinatlas.org/search/NR4A3"},"hgnc":{"alias_symbol":["CSMF","CHN","NOR1","MINOR"],"prev_symbol":[]},"alphafold":{"accession":"Q92570","domains":[{"cath_id":"3.30.50.10","chopping":"289-364","consensus_level":"medium","plddt":95.0051,"start":289,"end":364},{"cath_id":"1.10.565.10","chopping":"397-622","consensus_level":"high","plddt":90.8854,"start":397,"end":622}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q92570","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q92570-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q92570-F1-predicted_aligned_error_v6.png","plddt_mean":64.25},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=NR4A3","jax_strain_url":"https://www.jax.org/strain/search?query=NR4A3"},"sequence":{"accession":"Q92570","fasta_url":"https://rest.uniprot.org/uniprotkb/Q92570.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q92570/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q92570"}},"corpus_meta":[{"pmid":"17515897","id":"PMC_17515897","title":"Abrogation of nuclear receptors Nr4a3 and Nr4a1 leads to development of acute myeloid leukemia.","date":"2007","source":"Nature medicine","url":"https://pubmed.ncbi.nlm.nih.gov/17515897","citation_count":274,"is_preprint":false},{"pmid":"23074130","id":"PMC_23074130","title":"The significant other: splicing by the minor spliceosome.","date":"2012","source":"Wiley interdisciplinary reviews. RNA","url":"https://pubmed.ncbi.nlm.nih.gov/23074130","citation_count":253,"is_preprint":false},{"pmid":"23689062","id":"PMC_23689062","title":"L2, the minor capsid protein of papillomavirus.","date":"2013","source":"Virology","url":"https://pubmed.ncbi.nlm.nih.gov/23689062","citation_count":179,"is_preprint":false},{"pmid":"16430309","id":"PMC_16430309","title":"Significance of the minor cytochrome P450 3A isoforms.","date":"2006","source":"Clinical pharmacokinetics","url":"https://pubmed.ncbi.nlm.nih.gov/16430309","citation_count":176,"is_preprint":false},{"pmid":"30664630","id":"PMC_30664630","title":"Enhancer hijacking activates oncogenic transcription factor NR4A3 in acinic cell carcinomas of the salivary glands.","date":"2019","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/30664630","citation_count":163,"is_preprint":false},{"pmid":"9204277","id":"PMC_9204277","title":"Targeting the minor groove of DNA.","date":"1997","source":"Current opinion in structural biology","url":"https://pubmed.ncbi.nlm.nih.gov/9204277","citation_count":160,"is_preprint":false},{"pmid":"17055530","id":"PMC_17055530","title":"What drives proteins into the major or minor grooves of DNA?","date":"2006","source":"Journal of molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/17055530","citation_count":146,"is_preprint":false},{"pmid":"7663124","id":"PMC_7663124","title":"Complexes of the minor groove of DNA.","date":"1995","source":"Annual review of biophysics and biomolecular structure","url":"https://pubmed.ncbi.nlm.nih.gov/7663124","citation_count":145,"is_preprint":false},{"pmid":"36350986","id":"PMC_36350986","title":"BLIMP1 and NR4A3 transcription factors reciprocally regulate antitumor CAR T cell stemness and exhaustion.","date":"2022","source":"Science translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/36350986","citation_count":111,"is_preprint":false},{"pmid":"22366038","id":"PMC_22366038","title":"Thermospermine is not a minor polyamine in the plant kingdom.","date":"2012","source":"Plant & cell physiology","url":"https://pubmed.ncbi.nlm.nih.gov/22366038","citation_count":99,"is_preprint":false},{"pmid":"31094928","id":"PMC_31094928","title":"Nuclear NR4A3 Immunostaining Is a Specific and Sensitive Novel Marker for Acinic Cell Carcinoma of the Salivary Glands.","date":"2019","source":"The American journal of surgical pathology","url":"https://pubmed.ncbi.nlm.nih.gov/31094928","citation_count":96,"is_preprint":false},{"pmid":"35365367","id":"PMC_35365367","title":"Transsulfuration, minor player or crucial for cysteine homeostasis in cancer.","date":"2022","source":"Trends in cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/35365367","citation_count":93,"is_preprint":false},{"pmid":"28310880","id":"PMC_28310880","title":"Proximate biochemical composition and caloric content calculated from elemental CHN analysis: a stoichiometric concept.","date":"1984","source":"Oecologia","url":"https://pubmed.ncbi.nlm.nih.gov/28310880","citation_count":92,"is_preprint":false},{"pmid":"12493008","id":"PMC_12493008","title":"The immunogenomics of minor histocompatibility antigens.","date":"2002","source":"Immunological reviews","url":"https://pubmed.ncbi.nlm.nih.gov/12493008","citation_count":90,"is_preprint":false},{"pmid":"33648264","id":"PMC_33648264","title":"Nutritional and antinutritional composition of fava bean (Vicia faba L., var. minor) cultivars.","date":"2020","source":"Food research international (Ottawa, Ont.)","url":"https://pubmed.ncbi.nlm.nih.gov/33648264","citation_count":88,"is_preprint":false},{"pmid":"24706823","id":"PMC_24706823","title":"Nkx6.1 regulates islet β-cell proliferation via Nr4a1 and Nr4a3 nuclear receptors.","date":"2014","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/24706823","citation_count":84,"is_preprint":false},{"pmid":"18945812","id":"PMC_18945812","title":"Inhibition of adipocyte differentiation by Nur77, Nurr1, and Nor1.","date":"2008","source":"Molecular endocrinology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/18945812","citation_count":83,"is_preprint":false},{"pmid":"23990782","id":"PMC_23990782","title":"The Merkel cell polyomavirus minor capsid protein.","date":"2013","source":"PLoS pathogens","url":"https://pubmed.ncbi.nlm.nih.gov/23990782","citation_count":80,"is_preprint":false},{"pmid":"20558821","id":"PMC_20558821","title":"Deficiency of the NR4A orphan nuclear receptor NOR1 decreases monocyte adhesion and atherosclerosis.","date":"2010","source":"Circulation research","url":"https://pubmed.ncbi.nlm.nih.gov/20558821","citation_count":77,"is_preprint":false},{"pmid":"24746215","id":"PMC_24746215","title":"Extraskeletal myxoid chondrosarcoma with non-EWSR1-NR4A3 variant fusions correlate with rhabdoid phenotype and high-grade morphology.","date":"2014","source":"Human pathology","url":"https://pubmed.ncbi.nlm.nih.gov/24746215","citation_count":77,"is_preprint":false},{"pmid":"38629274","id":"PMC_38629274","title":"Orphan Nuclear Receptor NR4A3 Promotes Vascular Calcification via Histone Lactylation.","date":"2024","source":"Circulation research","url":"https://pubmed.ncbi.nlm.nih.gov/38629274","citation_count":76,"is_preprint":false},{"pmid":"24921003","id":"PMC_24921003","title":"Role of PRMTs in cancer: Could minor isoforms be leaving a mark?","date":"2014","source":"World journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/24921003","citation_count":76,"is_preprint":false},{"pmid":"10875239","id":"PMC_10875239","title":"Nuclear receptors Nor1 and NGFI-B/Nur77 play similar, albeit distinct, roles in the hypothalamo-pituitary-adrenal axis.","date":"2000","source":"Endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/10875239","citation_count":75,"is_preprint":false},{"pmid":"33509932","id":"PMC_33509932","title":"Structure of the activated human minor spliceosome.","date":"2021","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/33509932","citation_count":71,"is_preprint":false},{"pmid":"10602519","id":"PMC_10602519","title":"Fusion of the RBP56 and CHN genes in extraskeletal myxoid chondrosarcomas with translocation t(9;17)(q22;q11).","date":"1999","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/10602519","citation_count":64,"is_preprint":false},{"pmid":"16141523","id":"PMC_16141523","title":"Prostaglandin A2 acts as a transactivator for NOR1 (NR4A3) within the nuclear receptor superfamily.","date":"2005","source":"Biological & pharmaceutical bulletin","url":"https://pubmed.ncbi.nlm.nih.gov/16141523","citation_count":61,"is_preprint":false},{"pmid":"12216941","id":"PMC_12216941","title":"Minor H antigens: genes and peptides.","date":"2002","source":"Transplant immunology","url":"https://pubmed.ncbi.nlm.nih.gov/12216941","citation_count":60,"is_preprint":false},{"pmid":"28978703","id":"PMC_28978703","title":"Atomic Structures of Minor Proteins VI and VII in Human Adenovirus.","date":"2017","source":"Journal of virology","url":"https://pubmed.ncbi.nlm.nih.gov/28978703","citation_count":60,"is_preprint":false},{"pmid":"25410408","id":"PMC_25410408","title":"The nuclear orphan receptor NR4A1 and NR4A3 as tumor suppressors in hematologic neoplasms.","date":"2015","source":"Current drug targets","url":"https://pubmed.ncbi.nlm.nih.gov/25410408","citation_count":58,"is_preprint":false},{"pmid":"29343483","id":"PMC_29343483","title":"NR4A1 and NR4A3 restrict HSC proliferation via reciprocal regulation of C/EBPα and inflammatory signaling.","date":"2018","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/29343483","citation_count":57,"is_preprint":false},{"pmid":"22143616","id":"PMC_22143616","title":"The nuclear receptors NUR77, NURR1 and NOR1 in obesity and during fat loss.","date":"2011","source":"International journal of obesity (2005)","url":"https://pubmed.ncbi.nlm.nih.gov/22143616","citation_count":54,"is_preprint":false},{"pmid":"9368774","id":"PMC_9368774","title":"Minor histocompatibility antigens.","date":"1997","source":"Current opinion in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/9368774","citation_count":52,"is_preprint":false},{"pmid":"10773199","id":"PMC_10773199","title":"Differential patterns of induction of NGFI-B, Nor1 and c-fos mRNAs in striatal subregions by haloperidol and clozapine.","date":"2000","source":"Brain research","url":"https://pubmed.ncbi.nlm.nih.gov/10773199","citation_count":52,"is_preprint":false},{"pmid":"21725049","id":"PMC_21725049","title":"Down-regulation of the RUNX1-target gene NR4A3 contributes to hematopoiesis deregulation in familial platelet disorder/acute myelogenous leukemia.","date":"2011","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/21725049","citation_count":51,"is_preprint":false},{"pmid":"30455429","id":"PMC_30455429","title":"Orphan receptor NR4A3 is a novel target of p53 that contributes to apoptosis.","date":"2018","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/30455429","citation_count":47,"is_preprint":false},{"pmid":"11914082","id":"PMC_11914082","title":"Subcellular localization of chlorosome proteins in Chlorobium tepidum and characterization of three new chlorosome proteins: CsmF, CsmH, and CsmX.","date":"2002","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11914082","citation_count":47,"is_preprint":false},{"pmid":"31285338","id":"PMC_31285338","title":"The orphan nuclear receptor NR4A3 controls the differentiation of monocyte-derived dendritic cells following microbial stimulation.","date":"2019","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/31285338","citation_count":43,"is_preprint":false},{"pmid":"14555305","id":"PMC_14555305","title":"Thalassemia minor, the Gilbert mutation, and the risk of gallstones.","date":"2003","source":"Haematologica","url":"https://pubmed.ncbi.nlm.nih.gov/14555305","citation_count":42,"is_preprint":false},{"pmid":"29674002","id":"PMC_29674002","title":"Dengue virus NS2 and NS4: Minor proteins, mammoth roles.","date":"2018","source":"Biochemical pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/29674002","citation_count":40,"is_preprint":false},{"pmid":"20411565","id":"PMC_20411565","title":"Protein kinase C regulates mitochondrial targeting of Nur77 and its family member Nor-1 in thymocytes undergoing apoptosis.","date":"2010","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/20411565","citation_count":40,"is_preprint":false},{"pmid":"11673470","id":"PMC_11673470","title":"The EWS/NOR1 fusion gene product gains a novel activity affecting pre-mRNA splicing.","date":"2001","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11673470","citation_count":39,"is_preprint":false},{"pmid":"21803736","id":"PMC_21803736","title":"NOR1 is an HSF1- and NRF1-regulated putative tumor suppressor inactivated by promoter hypermethylation in nasopharyngeal carcinoma.","date":"2011","source":"Carcinogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/21803736","citation_count":38,"is_preprint":false},{"pmid":"31701670","id":"PMC_31701670","title":"The pro-inflammatory effect of NR4A3 in osteoarthritis.","date":"2019","source":"Journal of cellular and molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/31701670","citation_count":37,"is_preprint":false},{"pmid":"34768801","id":"PMC_34768801","title":"NR4A3: A Key Nuclear Receptor in Vascular Biology, Cardiovascular Remodeling, and Beyond.","date":"2021","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/34768801","citation_count":36,"is_preprint":false},{"pmid":"32910350","id":"PMC_32910350","title":"NR4A3 Immunohistochemistry Reliably Discriminates Acinic Cell Carcinoma from Mimics.","date":"2020","source":"Head and neck pathology","url":"https://pubmed.ncbi.nlm.nih.gov/32910350","citation_count":36,"is_preprint":false},{"pmid":"28066330","id":"PMC_28066330","title":"Muscle Contraction Induces Acute Hydroxymethylation of the Exercise-Responsive Gene Nr4a3.","date":"2016","source":"Frontiers in endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/28066330","citation_count":36,"is_preprint":false},{"pmid":"18327658","id":"PMC_18327658","title":"Oligodendroglial cells and neurotrophins: a polyphonic cantata in major and minor.","date":"2008","source":"Journal of molecular neuroscience : MN","url":"https://pubmed.ncbi.nlm.nih.gov/18327658","citation_count":36,"is_preprint":false},{"pmid":"32913051","id":"PMC_32913051","title":"Early programming of CD8+ T cell response by the orphan nuclear receptor NR4A3.","date":"2020","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/32913051","citation_count":36,"is_preprint":false},{"pmid":"25625556","id":"PMC_25625556","title":"The orphan receptor NOR1 participates in isoprenaline-induced cardiac hypertrophy by regulating PARP-1.","date":"2015","source":"British journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/25625556","citation_count":35,"is_preprint":false},{"pmid":"11881817","id":"PMC_11881817","title":"Minor H antigens: genes and peptides.","date":"2001","source":"European journal of immunogenetics : official journal of the British Society for Histocompatibility and Immunogenetics","url":"https://pubmed.ncbi.nlm.nih.gov/11881817","citation_count":35,"is_preprint":false},{"pmid":"29377304","id":"PMC_29377304","title":"Regulation of human trophoblast cell syncytialization by transcription factors STAT5B and NR4A3.","date":"2018","source":"Journal of cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/29377304","citation_count":35,"is_preprint":false},{"pmid":"30076719","id":"PMC_30076719","title":"MicroRNA-638 inhibits human airway smooth muscle cell proliferation and migration through targeting cyclin D1 and NOR1.","date":"2018","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/30076719","citation_count":35,"is_preprint":false},{"pmid":"32416215","id":"PMC_32416215","title":"Pharmacological potential of varinic-, minor-, and acidic phytocannabinoids.","date":"2020","source":"Pharmacological research","url":"https://pubmed.ncbi.nlm.nih.gov/32416215","citation_count":33,"is_preprint":false},{"pmid":"28893954","id":"PMC_28893954","title":"The Orphan Nuclear Receptor NR4A3 Is Involved in the Function of Dendritic Cells.","date":"2017","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/28893954","citation_count":33,"is_preprint":false},{"pmid":"27820700","id":"PMC_27820700","title":"The transcription factor NR4A3 controls CD103+ dendritic cell migration.","date":"2016","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/27820700","citation_count":31,"is_preprint":false},{"pmid":"25037369","id":"PMC_25037369","title":"Chemical characterisation and analysis of the cell wall polysaccharides of duckweed (Lemna minor).","date":"2014","source":"Carbohydrate polymers","url":"https://pubmed.ncbi.nlm.nih.gov/25037369","citation_count":29,"is_preprint":false},{"pmid":"31020999","id":"PMC_31020999","title":"NR4A3 fusion proteins trigger an axon guidance switch that marks the difference between EWSR1 and TAF15 translocated extraskeletal myxoid chondrosarcomas.","date":"2019","source":"The Journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/31020999","citation_count":28,"is_preprint":false},{"pmid":"30696767","id":"PMC_30696767","title":"The orphan nuclear receptor Nor1/Nr4a3 is a negative regulator of β-cell mass.","date":"2019","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/30696767","citation_count":28,"is_preprint":false},{"pmid":"31318053","id":"PMC_31318053","title":"Minor collagens of the skin with not so minor functions.","date":"2017","source":"Journal of anatomy","url":"https://pubmed.ncbi.nlm.nih.gov/31318053","citation_count":27,"is_preprint":false},{"pmid":"26934447","id":"PMC_26934447","title":"Significance of the NOR1-FOXA1/HDAC2-Slug regulatory network in epithelial-mesenchymal transition of tumor cells.","date":"2016","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/26934447","citation_count":27,"is_preprint":false},{"pmid":"17961535","id":"PMC_17961535","title":"A mutation in CHN-1/CHIP suppresses muscle degeneration in Caenorhabditis elegans.","date":"2007","source":"Developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/17961535","citation_count":26,"is_preprint":false},{"pmid":"32323598","id":"PMC_32323598","title":"miR-106b-5p induces immune imbalance of Treg/Th17 in immune thrombocytopenic purpura through NR4A3/Foxp3 pathway.","date":"2020","source":"Cell cycle (Georgetown, Tex.)","url":"https://pubmed.ncbi.nlm.nih.gov/32323598","citation_count":26,"is_preprint":false},{"pmid":"27144290","id":"PMC_27144290","title":"The Nuclear Receptor, Nor-1, Induces the Physiological Responses Associated With Exercise.","date":"2016","source":"Molecular endocrinology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/27144290","citation_count":26,"is_preprint":false},{"pmid":"33660780","id":"PMC_33660780","title":"Disruption of exon-bridging interactions between the minor and major spliceosomes results in alternative splicing around minor introns.","date":"2021","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/33660780","citation_count":26,"is_preprint":false},{"pmid":"29227538","id":"PMC_29227538","title":"Abberent expression of NOR1 protein in tumor associated macrophages contributes to the development of DEN-induced hepatocellular carcinoma.","date":"2018","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/29227538","citation_count":25,"is_preprint":false},{"pmid":"32057731","id":"PMC_32057731","title":"Resveratrol prevented experimental pulmonary vascular remodeling via miR-638 regulating NR4A3/cyclin D1 pathway.","date":"2020","source":"Microvascular research","url":"https://pubmed.ncbi.nlm.nih.gov/32057731","citation_count":25,"is_preprint":false},{"pmid":"24806827","id":"PMC_24806827","title":"Deficiency of the NR4A orphan nuclear receptor NOR1 in hematopoietic stem cells accelerates atherosclerosis.","date":"2014","source":"Stem cells (Dayton, Ohio)","url":"https://pubmed.ncbi.nlm.nih.gov/24806827","citation_count":25,"is_preprint":false},{"pmid":"26634653","id":"PMC_26634653","title":"Antithrombotic Effects of Nur77 and Nor1 Are Mediated Through Upregulating Thrombomodulin Expression in Endothelial Cells.","date":"2015","source":"Arteriosclerosis, thrombosis, and vascular biology","url":"https://pubmed.ncbi.nlm.nih.gov/26634653","citation_count":24,"is_preprint":false},{"pmid":"35059772","id":"PMC_35059772","title":"Dihydroartemisinin alleviates AngII-induced vascular smooth muscle cell proliferation and inflammatory response by blocking the FTO/NR4A3 axis.","date":"2022","source":"Inflammation research : official journal of the European Histamine Research Society ... [et al.]","url":"https://pubmed.ncbi.nlm.nih.gov/35059772","citation_count":24,"is_preprint":false},{"pmid":"1916933","id":"PMC_1916933","title":"Minor histocompatibility antigens.","date":"1991","source":"Immunology letters","url":"https://pubmed.ncbi.nlm.nih.gov/1916933","citation_count":23,"is_preprint":false},{"pmid":"34124809","id":"PMC_34124809","title":"SMARCA2-NR4A3 is a novel fusion gene of extraskeletal myxoid chondrosarcoma identified by RNA next-generation sequencing.","date":"2021","source":"Genes, chromosomes & cancer","url":"https://pubmed.ncbi.nlm.nih.gov/34124809","citation_count":23,"is_preprint":false},{"pmid":"32125766","id":"PMC_32125766","title":"Long non-coding RNA LINC00467 drives hepatocellular carcinoma progression via inhibiting NR4A3.","date":"2020","source":"Journal of cellular and molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/32125766","citation_count":22,"is_preprint":false},{"pmid":"34925506","id":"PMC_34925506","title":"MiR-20a-5p Negatively Regulates NR4A3 to Promote Metastasis in Bladder Cancer.","date":"2021","source":"Journal of oncology","url":"https://pubmed.ncbi.nlm.nih.gov/34925506","citation_count":22,"is_preprint":false},{"pmid":"31225466","id":"PMC_31225466","title":"The emerging role of minor intron splicing in neurological disorders.","date":"2018","source":"Cell stress","url":"https://pubmed.ncbi.nlm.nih.gov/31225466","citation_count":22,"is_preprint":false},{"pmid":"31498019","id":"PMC_31498019","title":"Radiotherapy in combination with hyperthermia suppresses lung cancer progression via increased NR4A3 and KLF11 expression.","date":"2019","source":"International journal of radiation biology","url":"https://pubmed.ncbi.nlm.nih.gov/31498019","citation_count":22,"is_preprint":false},{"pmid":"1887503","id":"PMC_1887503","title":"Minor histocompatibility antigens.","date":"1991","source":"Trends in genetics : TIG","url":"https://pubmed.ncbi.nlm.nih.gov/1887503","citation_count":22,"is_preprint":false},{"pmid":"20659174","id":"PMC_20659174","title":"Replicated association of the NR4A3 gene with smoking behaviour in schizophrenia and in bipolar disorder.","date":"2010","source":"Genes, brain, and behavior","url":"https://pubmed.ncbi.nlm.nih.gov/20659174","citation_count":21,"is_preprint":false},{"pmid":"31798628","id":"PMC_31798628","title":"An Integrated Model of Minor Intron Emergence and Conservation.","date":"2019","source":"Frontiers in genetics","url":"https://pubmed.ncbi.nlm.nih.gov/31798628","citation_count":21,"is_preprint":false},{"pmid":"32323756","id":"PMC_32323756","title":"miR‑106b‑5p modulates acute pulmonary embolism via NOR1 in pulmonary artery smooth muscle cells.","date":"2020","source":"International journal of molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/32323756","citation_count":20,"is_preprint":false},{"pmid":"34248958","id":"PMC_34248958","title":"Transcriptional Profiling of Monocytes Deficient in Nuclear Orphan Receptors NR4A2 and NR4A3 Reveals Distinct Signalling Roles Related to Antigen Presentation and Viral Response.","date":"2021","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/34248958","citation_count":19,"is_preprint":false},{"pmid":"15262426","id":"PMC_15262426","title":"Coexpression of NOR1 and SIX3 proteins in extraskeletal myxoid chondrosarcomas without detectable NR4A3 fusion genes.","date":"2004","source":"Cancer genetics and cytogenetics","url":"https://pubmed.ncbi.nlm.nih.gov/15262426","citation_count":19,"is_preprint":false},{"pmid":"19682370","id":"PMC_19682370","title":"Common polymorphisms within the NR4A3 locus, encoding the orphan nuclear receptor Nor-1, are associated with enhanced beta-cell function in non-diabetic subjects.","date":"2009","source":"BMC medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/19682370","citation_count":19,"is_preprint":false},{"pmid":"28666984","id":"PMC_28666984","title":"The nuclear receptor NOR-1/NR4A3 regulates the multifunctional glycoprotein vitronectin in human vascular smooth muscle cells.","date":"2017","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/28666984","citation_count":18,"is_preprint":false},{"pmid":"39098108","id":"PMC_39098108","title":"NR4A3 prevents diabetes induced atrial cardiomyopathy by maintaining mitochondrial energy metabolism and reducing oxidative stress.","date":"2024","source":"EBioMedicine","url":"https://pubmed.ncbi.nlm.nih.gov/39098108","citation_count":17,"is_preprint":false},{"pmid":"20551659","id":"PMC_20551659","title":"Histopathology of the minor duodenal papilla.","date":"2010","source":"Digestive surgery","url":"https://pubmed.ncbi.nlm.nih.gov/20551659","citation_count":17,"is_preprint":false},{"pmid":"34175686","id":"PMC_34175686","title":"Circ_0030586 inhibits cell proliferation and stemness in bladder cancer by inactivating the ERK signaling via miR-665/NR4A3 axis.","date":"2021","source":"Acta histochemica","url":"https://pubmed.ncbi.nlm.nih.gov/34175686","citation_count":17,"is_preprint":false},{"pmid":"24022864","id":"PMC_24022864","title":"6-Mercaptopurine augments glucose transport activity in skeletal muscle cells in part via a mechanism dependent upon orphan nuclear receptor NR4A3.","date":"2013","source":"American journal of physiology. Endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/24022864","citation_count":17,"is_preprint":false},{"pmid":"27181368","id":"PMC_27181368","title":"The nuclear receptor NOR-1 regulates the small muscle protein, X-linked (SMPX) and myotube differentiation.","date":"2016","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/27181368","citation_count":16,"is_preprint":false},{"pmid":"20645762","id":"PMC_20645762","title":"Cytotoxicity of Vinca minor.","date":"2010","source":"Pharmaceutical biology","url":"https://pubmed.ncbi.nlm.nih.gov/20645762","citation_count":15,"is_preprint":false},{"pmid":"16661102","id":"PMC_16661102","title":"Stress and Protein Turnover in Lemna minor.","date":"1979","source":"Plant physiology","url":"https://pubmed.ncbi.nlm.nih.gov/16661102","citation_count":15,"is_preprint":false},{"pmid":"30912283","id":"PMC_30912283","title":"Skeletal muscle Nur77 and NOR1 insulin responsiveness is blunted in obesity and type 2 diabetes but improved after exercise training.","date":"2019","source":"Physiological reports","url":"https://pubmed.ncbi.nlm.nih.gov/30912283","citation_count":14,"is_preprint":false},{"pmid":"27212070","id":"PMC_27212070","title":"Selective anti-malarial minor groove binders.","date":"2016","source":"Bioorganic & medicinal chemistry letters","url":"https://pubmed.ncbi.nlm.nih.gov/27212070","citation_count":14,"is_preprint":false},{"pmid":"36828363","id":"PMC_36828363","title":"NR4A3 Expression Is Consistently Absent in Acinic Cell Carcinomas of the Breast: A Potential Nosologic Shift.","date":"2023","source":"Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc","url":"https://pubmed.ncbi.nlm.nih.gov/36828363","citation_count":14,"is_preprint":false},{"pmid":"29047330","id":"PMC_29047330","title":"Deletion of the NR4A nuclear receptor NOR1 in hematopoietic stem cells reduces inflammation but not abdominal aortic aneurysm formation.","date":"2017","source":"BMC cardiovascular disorders","url":"https://pubmed.ncbi.nlm.nih.gov/29047330","citation_count":14,"is_preprint":false},{"pmid":"38508521","id":"PMC_38508521","title":"Expanding the Spectrum of NR4A3 Fusion-Positive Gynecologic Leiomyosarcomas.","date":"2024","source":"Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc","url":"https://pubmed.ncbi.nlm.nih.gov/38508521","citation_count":13,"is_preprint":false},{"pmid":"23036966","id":"PMC_23036966","title":"Minor withanolides of Physalis longifolia: structure and cytotoxicity.","date":"2012","source":"Chemical & pharmaceutical bulletin","url":"https://pubmed.ncbi.nlm.nih.gov/23036966","citation_count":13,"is_preprint":false},{"pmid":"11962767","id":"PMC_11962767","title":"Intergenic mRNAs. Minor gene products or tools of diversity?","date":"2002","source":"Histology and histopathology","url":"https://pubmed.ncbi.nlm.nih.gov/11962767","citation_count":13,"is_preprint":false},{"pmid":"35994844","id":"PMC_35994844","title":"Stress-induced immunosuppression affecting avian influenza virus vaccine immune response through miR-20a-5p/NR4A3 pathway in chicken.","date":"2022","source":"Veterinary microbiology","url":"https://pubmed.ncbi.nlm.nih.gov/35994844","citation_count":12,"is_preprint":false},{"pmid":"33221345","id":"PMC_33221345","title":"NR4A3 induces endothelial dysfunction through up-regulation of endothelial 1 expression in adipose tissue-derived stromal cells.","date":"2020","source":"Life sciences","url":"https://pubmed.ncbi.nlm.nih.gov/33221345","citation_count":12,"is_preprint":false},{"pmid":"15523651","id":"PMC_15523651","title":"Functional characterization of SIX3 homeodomain mutations in holoprosencephaly: interaction with the nuclear receptor NR4A3/NOR1.","date":"2004","source":"Human mutation","url":"https://pubmed.ncbi.nlm.nih.gov/15523651","citation_count":12,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":48724,"output_tokens":8844,"usd":0.139416},"stage2":{"model":"claude-opus-4-6","input_tokens":12663,"output_tokens":4235,"usd":0.253785},"total_usd":0.393201,"stage1_batch_id":"msgbatch_012ZiiCUBfB62NCTQd4Bk1Jo","stage2_batch_id":"msgbatch_01Xuqq9aUHoQouS7UVGZNStZ","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2007,\n      \"finding\": \"Abrogation of both NR4A3 (Nor-1) and NR4A1 (Nur77) in mice leads to rapidly lethal acute myeloid leukemia involving abnormal expansion of hematopoietic stem cells and myeloid progenitors, decreased expression of AP-1 transcription factors JunB and c-Jun, and defective extrinsic apoptotic (Fas-L and TRAIL) signaling, establishing NR4A3 as a tumor suppressor of myeloid leukemogenesis.\",\n      \"method\": \"Genetic knockout mouse model (double Nr4a1/Nr4a3 knockout) with phenotypic readout (AML development, HSC expansion, apoptotic signaling analysis)\",\n      \"journal\": \"Nature medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — clean KO with defined cellular phenotype, replicated in human AML patient samples\",\n      \"pmids\": [\"17515897\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"NR4A3 (Nor1) is expressed in the pituitary gland and adrenal cortex; ACTH and angiotensin II treatment induces Nor1 expression in adrenal fasciculata cells; Nor1 activates steroidogenic enzyme genes (e.g., P450c21) through binding to NGFI-B response element (NBRE) promoter sequences; transcriptional regulation of Nor1 in adrenal cells depends on protein kinase A and protein kinase C cascades.\",\n      \"method\": \"Transactivation reporter assays, binding experiments with NBRE and NurRE sequences, pharmacological inhibition of PKA/PKC pathways\",\n      \"journal\": \"Endocrinology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — functional reporter assays and pharmacological dissection, single lab\",\n      \"pmids\": [\"10875239\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"Prostaglandin A2 (PGA2) acts as a transactivator for NR4A3 (NOR1) by directly binding to the ligand-binding domain (LBD) of NOR1 and activating NOR1-dependent transcription; LBD-deleted NOR1 shows little transcriptional activation by PGA2.\",\n      \"method\": \"GAL4-based reporter system, direct LBD binding assay, transgenic mouse-derived spleen cell sensitivity assay\",\n      \"journal\": \"Biological & pharmaceutical bulletin\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1-2 — direct LBD binding and reporter assay, single lab\",\n      \"pmids\": [\"16141523\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"The EWS/NOR1 fusion protein (arising from chromosomal translocation in extraskeletal myxoid chondrosarcoma) gains a novel activity affecting pre-mRNA splicing: it complements loss of function of yeast splicing factor Snu23p, causes increased usage of distal 5'-splice sites in mammalian cells, and interacts with the human splicing protein U1C—activities not possessed by EWS or NOR1 alone.\",\n      \"method\": \"Functional complementation screening in yeast, pre-mRNA splicing assay in mammalian cells, co-immunoprecipitation with U1C splicing protein\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — multiple orthogonal methods (yeast complementation, mammalian splicing assay, Co-IP), single lab with strong mechanistic rigor\",\n      \"pmids\": [\"11673470\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"In extraskeletal myxoid chondrosarcoma with t(9;17)(q22;q11), the NR4A3 (CHN/TEC) gene fuses with RBP56 (TAF15) to generate a chimeric RBP56/CHN oncogenic fusion, demonstrating that the N-terminal transactivation domains of EWS and RBP56 are pathogenetically equivalent when fused to NR4A3.\",\n      \"method\": \"Molecular cloning, RT-PCR, chromosomal translocation breakpoint analysis\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — molecularly characterized fusion gene confirmed in patient samples, replicated across EMC literature\",\n      \"pmids\": [\"10602519\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"NR4A3 (Nor-1) in endothelial cells is rapidly induced by inflammatory stimuli through NF-κB-dependent transactivation of the NOR1 promoter; NOR1 induces VCAM-1 promoter activity by directly binding to a canonical NR4A response element in the VCAM-1 promoter (confirmed by ChIP and transient transfection); NOR1 deficiency in apoE-/- mice reduces atherosclerosis by decreasing macrophage content.\",\n      \"method\": \"ChIP assay, transient transfection with VCAM-1 promoter-reporter constructs, NOR1-deficient mouse atherosclerosis model, monocyte adhesion functional assay\",\n      \"journal\": \"Circulation research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — ChIP confirms direct promoter binding, functional in vivo validation in knockout mice\",\n      \"pmids\": [\"20558821\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"NR4A3 (Nor-1) translocates from the nucleus to mitochondria in thymocytes undergoing apoptosis; this translocation requires phosphorylation by PKC (both classical and novel isoforms); Nor-1 associates with Bcl-2 in the mitochondria, inducing a conformational change that exposes the Bcl-2 BH3 domain.\",\n      \"method\": \"PKC inhibitor pharmacology, phosphorylation analysis, subcellular fractionation/translocation assay, Bcl-2 BH3 conformation assay in thymocytes\",\n      \"journal\": \"European journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — localization with functional consequence and mechanistic follow-up, single lab\",\n      \"pmids\": [\"20411565\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Nkx6.1 induces expression of Nr4a3 (and Nr4a1) in pancreatic islets; Nr4a3 is both necessary and sufficient for Nkx6.1-mediated β-cell proliferation; Nr4a3 increases expression of cell cycle inducers E2F1 and cyclin E1, and induces components of the anaphase-promoting complex (including UBE2C), leading to degradation of the cell cycle inhibitor p21.\",\n      \"method\": \"Adenoviral overexpression, siRNA knockdown, global Nr4a1 knockout mice, gene expression analysis\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — necessity and sufficiency experiments with defined molecular pathway, multiple methods\",\n      \"pmids\": [\"24706823\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Retroviral overexpression of NR4A3 (NOR1) in 3T3-L1 or 3T3-F442A preadipocytes potently inhibits adipogenesis in a manner that cannot be rescued by PPARγ overexpression or activation; NR4A3 inhibits mitotic clonal expansion of preadipocytes; NOR1 (and family members Nur77 and Nurr1) upregulate gap-junction protein Gja1 and Tll1 as downstream mediators.\",\n      \"method\": \"Retroviral transduction, adipogenesis assays, transcriptional profiling, retroviral expression of target genes\",\n      \"journal\": \"Molecular endocrinology (Baltimore, Md.)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — gain-of-function with defined cellular phenotype and target gene identification, single lab\",\n      \"pmids\": [\"18945812\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"NR4A3 is a direct transcriptional target of RUNX1; downregulation of NR4A3 in RUNX1-mutated hematopoietic progenitors increases clonogenic potential; restoration of NR4A3 expression partially reduces the clonogenic potential of patient progenitors from familial platelet disorder/AML pedigrees.\",\n      \"method\": \"ChIP demonstrating RUNX1 binding to NR4A3 promoter, lentiviral NR4A3 restoration in patient-derived CD34+ progenitors, clonogenic assays\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — direct ChIP evidence for RUNX1→NR4A3 regulation plus functional rescue in patient cells\",\n      \"pmids\": [\"21725049\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"NR4A3 is a direct transcriptional target of p53: p53 binds the promoter of NR4A3 and induces its transcription; NR4A3 overexpression promotes apoptosis by augmenting pro-apoptotic genes PUMA and Bax; NR4A3 physically interacts with anti-apoptotic Bcl-2 protein, sequestering it from inhibiting apoptosis.\",\n      \"method\": \"ChIP assay for p53 binding to NR4A3 promoter, luciferase reporter assay, Co-immunoprecipitation (NR4A3-Bcl-2 interaction), overexpression/knockdown with apoptosis readout\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — multiple orthogonal methods including ChIP, reporter assay, and Co-IP, single lab\",\n      \"pmids\": [\"30455429\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"NR4A1 and NR4A3 (NR4A1/3) restrict HSC proliferation by directly binding to a hematopoietic-specific Cebpa enhancer to activate C/EBPα transcription; NR4A1/3 also occupy regulatory regions of NF-κB-regulated inflammatory cytokines, antagonizing NF-κB signaling; conditional knockout of NR4A1/3 in HSCs causes loss of quiescence, accumulation of oxidative stress, DNA damage, and upregulation of cell cycle and inflammation programs.\",\n      \"method\": \"Conditional double knockout mouse model, ChIP-seq/genomic occupancy studies, molecular profiling of HSCs, NF-κB signaling analysis\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — direct genomic binding evidence plus conditional KO with defined HSC phenotype\",\n      \"pmids\": [\"29343483\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"NR4A3 (NOR-1) is essential for migration of CD103+ dendritic cells to lymph nodes; this defect is cell-intrinsic; NR4A3 deficiency causes marked loss of surface CCR7 expression specifically on CD103+ DCs (not T cells); NR4A3 maintains FOXO1 protein levels in CD103+ DCs through an AKT-dependent mechanism, and FOXO1 regulates CCR7 expression; NR4A3 is also required for homeostatic mitochondrial function in CD103+ DCs.\",\n      \"method\": \"Nr4a3-deficient mouse model, mixed bone marrow chimera (cell-intrinsic proof), flow cytometry for CCR7/FOXO1, AKT pathway inhibitor studies\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — cell-intrinsic KO with defined migration and molecular phenotype, multiple orthogonal approaches\",\n      \"pmids\": [\"27820700\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"NR4A3 is required for differentiation of monocytes into monocyte-derived dendritic cells (MoDCs) but not other DC types; Nr4a3-/- mice show severely impaired generation of DC-SIGN+ MoDCs in response to LPS, resulting in inability to mount optimal CD8+ T cell responses to gram-negative bacteria; transcriptomics shows NR4A3 skews monocyte fate toward MoDCs over macrophages and enables acquisition of migratory characteristics.\",\n      \"method\": \"Nr4a3-/- mouse model, flow cytometry, transcriptomic analysis, in vivo bacterial infection challenge\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic KO with defined differentiation phenotype, transcriptomic mechanism, and functional immune readout\",\n      \"pmids\": [\"31285338\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"NR4A3 deficiency in CD8+ T cells leads to preferential differentiation into memory precursor and central memory cells with increased cytokine production; NR4A3 deficiency early programs memory transcriptional programs and increases chromatin accessibility at bZIP transcription factor motifs, affecting Fos/Jun target gene transcription.\",\n      \"method\": \"NR4A3-deficient murine CD8+ T cells, ATAC-seq for chromatin accessibility, transcriptional profiling, cytokine production assays\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — KO with epigenomic and transcriptomic mechanism, multiple orthogonal methods\",\n      \"pmids\": [\"32913051\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Dual knockout of PRDM1 and NR4A3 in CAR T cells skews phenotypes away from TIM-3+CD8+ toward TCF1+CD8+, countering exhaustion and improving antitumor responses; NR4A3 is identified as part of an NFAT-driven T cell dysfunction program that is upregulated as negative epigenetic feedback when PRDM1 is deleted.\",\n      \"method\": \"CRISPR knockout (single and dual) in CAR T cells, scRNA-seq, in vivo tumor models\",\n      \"journal\": \"Science translational medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic epistasis with defined phenotypic readout, scRNA-seq mechanistic support, in vivo validation\",\n      \"pmids\": [\"36350986\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"NR4A3 (NOR1) physically interacts with PARP-1 (confirmed by co-immunoprecipitation); NOR1 overexpression enhances PARP-1 activity and promotes cardiac hypertrophy; a NOR1 mutant (C293Y) lacking PARP-1 binding activity fails to induce hypertrophy; PARP-1 inhibition or siRNA blocks NOR1-driven hypertrophic effects.\",\n      \"method\": \"Co-immunoprecipitation (NOR1-PARP-1), NOR1 overexpression/knockdown in neonatal rat cardiomyocytes, C293Y mutant analysis, PARP-1 activity assay, hypertrophy markers\",\n      \"journal\": \"British journal of pharmacology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — Co-IP plus mutagenesis and pharmacological validation, single lab with multiple orthogonal approaches\",\n      \"pmids\": [\"25625556\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"NR4A3 (Nor1) negatively regulates β-cell mass: Nor1 knockout mice display increased β-cell mass and improved glucose tolerance; Nor1 expression is induced by pro-inflammatory cytokines and elevated glucose; Nor1 overexpression in INS and human islet cells causes apoptosis, while siRNA-mediated Nor1 knockdown prevents cytokine-induced β-cell death.\",\n      \"method\": \"Nor1 knockout mouse histological analysis, lentiviral overexpression, siRNA knockdown in INS cells and human islets, apoptosis assays\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic KO plus gain/loss-of-function with defined β-cell phenotype, multiple methods\",\n      \"pmids\": [\"30696767\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"NR4A3 (NOR-1) directly regulates vitronectin (VTN) expression in human vascular smooth muscle cells by binding to an NBRE(-202/-195) site in the VTN promoter; NOR-1-driven VTN secretion promotes VSMC migration; this was confirmed by EMSA, ChIP, deletion and site-directed mutagenesis studies.\",\n      \"method\": \"Lentiviral NOR-1 overexpression/silencing, EMSA, ChIP, promoter deletion/mutagenesis with reporter assays, cell migration assay with anti-VTN blocking antibody\",\n      \"journal\": \"FASEB journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — direct DNA-binding confirmed by EMSA and ChIP with mutagenesis, functional consequence demonstrated\",\n      \"pmids\": [\"28666984\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"NR4A3 (NOR-1) expression is induced by exercise via calcium/calcineurin signaling in skeletal muscle; transgenic Nor-1 expression in skeletal muscle induces muscle hypertrophy, vascularization, and increased autophagy (elevated LC3A-II, autophagy protein 5 and 12, decreased p62, decreased mTORC1 activity).\",\n      \"method\": \"Transgenic Nor-1 mouse model, calcineurin inhibitor pharmacology, autophagy marker analysis (LC3A-GFP-RFP chimera), exercise studies\",\n      \"journal\": \"Molecular endocrinology (Baltimore, Md.)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — transgenic mouse model with defined metabolic phenotype and pathway analysis, single lab\",\n      \"pmids\": [\"27144290\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"NR4A3 (NOR-1) regulates the small muscle protein X-linked (SMPX) in human vascular smooth muscle cells and skeletal muscle cells by binding to a non-consensus NBRE site in the human SMPX promoter; NOR-1 silencing prevents SMPX expression and differentiation of human skeletal muscle myoblasts to myotubes.\",\n      \"method\": \"Lentiviral NOR-1 overexpression/silencing, transcriptional reporter assays, EMSA (DNA-protein binding), NOR-1 siRNA knockdown in HSMM differentiation\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — DNA-protein binding and reporter assays with loss-of-function, single lab\",\n      \"pmids\": [\"27181368\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"6-Mercaptopurine (6-MP) activates NR4A3 (NOR-1) and enhances glucose transport activity in L6 skeletal muscle cells via increased GLUT4 translocation in an NR4A3-dependent manner; 6-MP also increases phospho-AS160 through NR4A3-independent mechanisms.\",\n      \"method\": \"NR4A3 overexpression/knockdown in L6 cells, glucose transport assay, GLUT4 translocation assay, 6-MP pharmacology\",\n      \"journal\": \"American journal of physiology. Endocrinology and metabolism\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — gain/loss-of-function with defined metabolic phenotype, single lab\",\n      \"pmids\": [\"24022864\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"NR4A3 overexpression in mouse salivary gland cells increases expression of known NR4A3 target genes and stimulates cell proliferation; recurrent t(4;9)(q13;q31) chromosomal rearrangements in acinic cell carcinoma translocate active SCPP enhancer regions upstream of NR4A3, driving its ectopic overexpression (enhancer hijacking); active chromatin regions and gene expression signatures in AciCCs correlate with NR4A3 transcription factor binding motifs.\",\n      \"method\": \"Whole genome sequencing, RNA-seq, ATAC-seq/chromatin profiling, NR4A3 overexpression in salivary gland cells with proliferation assay\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multi-omic evidence plus functional overexpression, strong mechanistic support\",\n      \"pmids\": [\"30664630\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"NR4A3 (Nor1) and NR4A1 (Nur77) increase thrombomodulin expression in endothelial cells through distinct mechanisms: Nur77 increases thrombomodulin mRNA stability (not promoter activity), whereas Nor1 enhances thrombomodulin expression primarily through induction of Krüppel-like factors 2 and 4 (KLF2/4); both receptors increase protein C activity and inhibit prothrombotic effects.\",\n      \"method\": \"Adenovirus-mediated transduction of Nur77 and Nor1 cDNAs, mRNA stability assays, promoter activity assays, KLF2/4 expression analysis, protein C activity assay, Nur77-deficient mouse thrombosis model\",\n      \"journal\": \"Arteriosclerosis, thrombosis, and vascular biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — distinct mechanistic pathways demonstrated for Nor1, single lab with multiple approaches\",\n      \"pmids\": [\"26634653\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"NR4A3 promotes vascular calcification via histone lactylation: NR4A3 directly binds to promoters of glycolysis genes ALDOA and PFKL to drive their transcription, thereby enhancing glycolysis and lactate production; elevated lactate promotes histone lactylation, which in turn activates transcription of Phospho1 (PHOSPHO1), promoting calcium deposition; NR4A3 deficiency inhibits this cascade and reduces calcification.\",\n      \"method\": \"NR4A3-/- mouse models of medial arterial calcification, RNA-seq, CUT&TAG chromatin occupancy analysis, glycolysis/lactate assays, Phospho1 pharmacological inhibition and overexpression\",\n      \"journal\": \"Circulation research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — direct genomic binding evidence (CUT&TAG) plus multi-step mechanistic validation in KO mice and cell models\",\n      \"pmids\": [\"38629274\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Muscle contraction induces acute hydroxymethylation followed by demethylation of the NR4A3 promoter: electrical pulse stimulation causes early hydroxymethylation at the NR4A3 promoter (highest immediately post-EPS), followed by demethylation at 60 min and re-methylation at 120 min, accompanying transcriptional induction of NR4A3.\",\n      \"method\": \"Targeted bisulfite sequencing, hydroxymethylcytosine analysis, electrical pulse stimulation of C2C12 myotubes, acute exercise study in humans\",\n      \"journal\": \"Frontiers in endocrinology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct epigenetic mapping at NR4A3 promoter with temporal resolution, single lab\",\n      \"pmids\": [\"28066330\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"NR4A3 knockdown in bone marrow-derived dendritic cells suppresses TLR-mediated upregulation of CD80, CD86, IL-10, IL-6, and IL-12; NR4A3 knockdown decreases expression of IKKβ, IRF4, and IRF8; IKKβ mediates IL-10 and IL-6 induction while IRF4/IRF8 mediate IL-12 induction downstream of NR4A3.\",\n      \"method\": \"siRNA knockdown in bone marrow-derived DCs, cytokine and surface marker expression analysis, secondary siRNA knockdown of IKKβ/IRF4/IRF8\",\n      \"journal\": \"Journal of immunology (Baltimore, Md. : 1950)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — loss-of-function with defined molecular pathway via epistasis (secondary siRNA), single lab\",\n      \"pmids\": [\"28893954\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"NR4A3 knockdown in BeWo trophoblast cells increases FSK-induced cell fusion and expression of syncytialization markers (CGB, syncytin2), indicating that cAMP-PKA-upregulated NR4A3 acts as a negative regulator of syncytialization; NR4A3 counterbalances the positive regulator STAT5B in controlling the degree of trophoblast cell fusion.\",\n      \"method\": \"siRNA knockdown of NR4A3 in BeWo cells, microarray analysis, syncytialization assay (cell fusion), RT-PCR for syncytialization markers\",\n      \"journal\": \"Journal of cellular biochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — loss-of-function with defined cellular phenotype and molecular markers, single lab\",\n      \"pmids\": [\"29377304\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"NR4A3 (NOR1) physically interacts with the homeodomain transcription factor SIX3 and stimulates its transcriptional activity; the SIX3 holoprosencephaly mutation p.R257P abolishes the interaction with NOR1 in vivo, while p.L226V does not alter this interaction, demonstrating that different HPE2 SIX3 mutations affect distinct signaling pathways.\",\n      \"method\": \"GST fusion protein pull-down assays, transient co-transfection with expression and reporter vectors in Neuro-2a cells\",\n      \"journal\": \"Human mutation\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct protein-protein interaction with mutagenesis, single lab\",\n      \"pmids\": [\"15523651\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"NR4A3 plays a pro-inflammatory role in osteoarthritis chondrocytes by enhancing IL-1β-stimulated expression of matrix-degrading enzymes (MMP-3, MMP-9, iNOS, COX-2) and enhancing NF-κB activation; NR4A3 overexpression also enhances EBSS-induced chondrocyte apoptosis.\",\n      \"method\": \"Lentiviral overexpression and siRNA knockdown in chondrocytes, NF-κB signaling analysis, MMP/iNOS/COX-2 expression, apoptosis assay\",\n      \"journal\": \"Journal of cellular and molecular medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — gain/loss-of-function with defined pro-inflammatory pathway, single lab\",\n      \"pmids\": [\"31701670\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"miR-106b-5p targets the 3' UTR of NR4A3 mRNA and negatively regulates NR4A3 expression, thereby inducing Treg/Th17 immune imbalance in immune thrombocytopenic purpura; NR4A3 regulates Treg differentiation via Foxp3; sh-NR4A3 decreases Foxp3 and TGF-β expression.\",\n      \"method\": \"Dual-luciferase reporter assay (miR-106b-5p/NR4A3 3'UTR), qRT-PCR, western blot, sh-NR4A3 knockdown, in vivo silencing of miR-106b-5p\",\n      \"journal\": \"Cell cycle (Georgetown, Tex.)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct 3'UTR targeting confirmed by luciferase assay with in vivo validation, single lab\",\n      \"pmids\": [\"32323598\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"NR4A3 protects against diabetes-induced atrial remodeling by preserving mitochondrial energy metabolism and reducing oxidative stress; NR4A3 maintains transcriptional expression of Sdha (succinate dehydrogenase subunit A); NR4A3 deficiency exacerbates atrial fibrosis and increases AF susceptibility, while AAV9-mediated NR4A3 overexpression alleviates atrial remodeling in db/db mice.\",\n      \"method\": \"Nr4a3-/- mouse model, AAV9-Nr4a3 overexpression in db/db mice, RNA-seq, metabolomics, electrophysiological analysis, histological analysis\",\n      \"journal\": \"EBioMedicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — bidirectional genetic manipulation with defined molecular mechanism (Sdha regulation), single lab\",\n      \"pmids\": [\"39098108\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"NOR1 (NR4A3) cooperates with a FOXA1-HDAC2 complex to repress Slug transcription, inhibiting epithelial-mesenchymal transition in nasopharyngeal carcinoma; FOXA1 and HDAC2 bind the slug promoter and directly repress its transcription.\",\n      \"method\": \"Data mining of gene expression profiles, ectopic expression, RNA interference, chromatin-related functional assays\",\n      \"journal\": \"Oncotarget\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — mechanistic cooperation shown but primarily based on ectopic expression and RNAi without direct binding confirmation for NOR1 specifically\",\n      \"pmids\": [\"26934447\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"FTO (fat mass and obesity-associated protein) demethylates NR4A3 mRNA (m6A modification); FTO knockdown increases methylation of NR4A3 mRNA; DHA (dihydroartemisinin) suppresses AngII-induced VSMC proliferation and inflammation by inhibiting the FTO/NR4A3 axis.\",\n      \"method\": \"m6A-RIP assay (MeRIP), FTO knockdown/overexpression with mutant FTO control, CCK-8 proliferation assay, immunofluorescence\",\n      \"journal\": \"Inflammation research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct m6A modification on NR4A3 mRNA demonstrated by MeRIP with mutant control, single lab\",\n      \"pmids\": [\"35059772\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"NR4A3 (NOR-1) is a ligand-independent orphan nuclear receptor that functions as a transcription factor by binding NBRE and NurRE response elements to regulate target genes (VCAM-1, VTN, SMPX, ALDOA, PFKL, Cebpa, thrombomodulin via KLF2/4, Sdha) involved in inflammation, proliferation, apoptosis, and metabolism; it undergoes PKC-dependent nuclear-to-mitochondrial translocation where it interacts with Bcl-2 to promote apoptosis, physically associates with PARP-1 and SIX3, is directly transcriptionally induced by p53 and RUNX1, is activated by prostaglandin A2 through its LBD, and its mRNA is subject to FTO-mediated m6A modification; loss of NR4A3 (alone or with NR4A1) causes AML in mice through failure to maintain HSC quiescence and C/EBPα-driven antiproliferative programs, while in immunity NR4A3 is required for CD103+ DC migration via FOXO1/CCR7 and for monocyte-to-MoDC differentiation, and in T cells it programs CD8+ T cell fate toward effector over memory by driving exhaustion-associated transcriptional programs.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"NR4A3 (NOR-1) is an orphan nuclear receptor that functions as a ligand-independent transcription factor governing cell fate decisions across hematopoietic, vascular, metabolic, and immune lineages. It binds NBRE response elements in target gene promoters—including VCAM-1, VTN, SMPX, ALDOA, PFKL, and Cebpa—to regulate inflammation, proliferation, and metabolic programs [PMID:20558821, PMID:28666984, PMID:29343483, PMID:38629274]. Beyond its nuclear transcriptional role, NR4A3 undergoes PKC-dependent translocation to mitochondria where it interacts with Bcl-2 to expose its BH3 domain and promote apoptosis, and it is itself transcriptionally regulated by p53, RUNX1, and NF-κB [PMID:20411565, PMID:30455429, PMID:21725049]. Combined loss of NR4A3 and NR4A1 causes acute myeloid leukemia in mice through failure to maintain HSC quiescence and C/EBPα expression, while in the immune system NR4A3 is required for CD103+ dendritic cell migration via FOXO1/CCR7, monocyte-to-MoDC differentiation, and programming of CD8+ T cell effector versus memory fate [PMID:17515897, PMID:27820700, PMID:31285338, PMID:32913051].\",\n  \"teleology\": [\n    {\n      \"year\": 1999,\n      \"claim\": \"Identification of NR4A3 as a recurrent fusion partner in extraskeletal myxoid chondrosarcoma established that its transcriptional domains are oncogenically relevant when dysregulated, motivating study of its normal transcriptional function.\",\n      \"evidence\": \"Molecular cloning and breakpoint analysis of t(9;17) and t(4;9) translocations in EMC patient tumors\",\n      \"pmids\": [\"10602519\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism by which EWS-NR4A3 or TAF15-NR4A3 fusions drive sarcomagenesis not fully defined\", \"Whether wild-type NR4A3 has any role in chondrocyte biology was unknown\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Demonstration that NR4A3 binds NBRE promoter elements and activates steroidogenic gene transcription via PKA/PKC cascades established it as a functional transcription factor responsive to hormonal signaling.\",\n      \"evidence\": \"Reporter assays with NBRE sequences and PKA/PKC inhibitor pharmacology in adrenal fasciculata cells\",\n      \"pmids\": [\"10875239\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Endogenous chromatin occupancy not confirmed\", \"Whether NR4A3 has ligand-independent versus ligand-dependent activity was still debated\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"The EWS/NOR1 fusion was shown to gain a neomorphic splicing activity by interacting with U1C, demonstrating that the fusion creates functions absent from either partner alone.\",\n      \"evidence\": \"Yeast splicing complementation, mammalian splice-site assay, and co-immunoprecipitation with U1C\",\n      \"pmids\": [\"11673470\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Relevance of splicing disruption to EMC tumorigenesis not established\", \"Whether wild-type NR4A3 has any role in RNA processing is unknown\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Prostaglandin A2 was identified as a ligand that activates NR4A3 through direct binding to its LBD, partially resolving whether this 'orphan' receptor has physiological ligands.\",\n      \"evidence\": \"GAL4-LBD reporter system and direct LBD binding assay\",\n      \"pmids\": [\"16141523\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Physiological relevance of PGA2 as an endogenous NR4A3 ligand in vivo not confirmed\", \"Structural basis of LBD-PGA2 interaction not resolved\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Double knockout of NR4A3 and NR4A1 caused rapidly lethal AML with HSC expansion and defective extrinsic apoptosis, establishing NR4A3 as a bona fide tumor suppressor in myeloid leukemogenesis.\",\n      \"evidence\": \"Nr4a1/Nr4a3 double knockout mice with AML phenotype, validated against human AML samples\",\n      \"pmids\": [\"17515897\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Individual contribution of NR4A3 versus NR4A1 to leukemia suppression not separated\", \"Direct transcriptional targets mediating tumor suppression were unknown at this point\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Two parallel discoveries defined NR4A3's mechanism in vascular inflammation and apoptosis: ChIP demonstrated direct VCAM-1 promoter binding in endothelial cells, while subcellular fractionation showed PKC-dependent nuclear-to-mitochondrial translocation where NR4A3 engages Bcl-2 to expose its BH3 domain.\",\n      \"evidence\": \"ChIP and NOR1-deficient apoE−/− atherosclerosis model (VCAM-1); PKC inhibitor pharmacology and Bcl-2 BH3 conformation assay in thymocytes (apoptosis)\",\n      \"pmids\": [\"20558821\", \"20411565\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether mitochondrial translocation and transcriptional function are coordinated or independent programs\", \"Structural details of NR4A3-Bcl-2 interaction not resolved\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Identification of NR4A3 as a direct RUNX1 transcriptional target linked familial platelet disorder/AML predisposition to NR4A3 downregulation, explaining how RUNX1 mutations expand myeloid progenitors.\",\n      \"evidence\": \"ChIP showing RUNX1 binding to NR4A3 promoter; lentiviral NR4A3 restoration partially rescued clonogenicity in FPD/AML patient CD34+ cells\",\n      \"pmids\": [\"21725049\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether NR4A3 restoration alone is sufficient to prevent leukemic transformation in RUNX1-mutant settings\", \"Other RUNX1 targets may contribute in parallel\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"NR4A3 was shown to be necessary and sufficient for Nkx6.1-driven β-cell proliferation, operating through E2F1/cyclin E1 upregulation and APC-mediated p21 degradation, revealing a cell cycle–promoting role distinct from its tumor-suppressive function in hematopoiesis.\",\n      \"evidence\": \"Adenoviral overexpression and siRNA knockdown in islets, global Nr4a1 KO mice\",\n      \"pmids\": [\"24706823\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether NR4A3 directly binds E2F1 or cyclin E1 promoters not shown\", \"Context-dependent switch between pro-proliferative and anti-proliferative roles not mechanistically explained\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Discovery of a physical NR4A3–PARP-1 interaction that drives cardiac hypertrophy, with the C293Y mutation abolishing this interaction and hypertrophic response, established a non-transcriptional effector partnership for NR4A3.\",\n      \"evidence\": \"Co-immunoprecipitation, C293Y mutant analysis, PARP-1 activity assay, and hypertrophy markers in neonatal rat cardiomyocytes\",\n      \"pmids\": [\"25625556\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether PARP-1 activation requires NR4A3 transcriptional activity or is purely protein-protein\", \"In vivo cardiac phenotype of NR4A3 loss not reported\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Multiple studies established NR4A3's immune roles: it is essential for CD103+ DC migration via maintenance of FOXO1/CCR7, and it regulates TLR-mediated DC activation through IKKβ and IRF4/IRF8.\",\n      \"evidence\": \"Nr4a3-deficient mice with mixed bone marrow chimeras (cell-intrinsic DC migration defect); siRNA in BMDCs with epistatic knockdown of IKKβ/IRF4/IRF8\",\n      \"pmids\": [\"27820700\", \"28893954\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct transcriptional targets of NR4A3 that maintain FOXO1 protein levels not identified\", \"Whether NR4A3 directly binds IKKβ or IRF promoters unknown\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Direct NBRE-dependent regulation of vitronectin by NR4A3 in vascular smooth muscle cells was rigorously confirmed by EMSA, ChIP, and site-directed mutagenesis, linking NR4A3 to VSMC migration.\",\n      \"evidence\": \"EMSA, ChIP, promoter deletion/mutagenesis with reporter assays, migration assay with anti-VTN blocking antibody in human VSMCs\",\n      \"pmids\": [\"28666984\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo relevance to neointimal formation or vascular remodeling not demonstrated\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Two key advances resolved NR4A3's upstream regulation by p53 (direct promoter binding inducing apoptosis via PUMA/Bax) and its direct role in HSC quiescence through binding the Cebpa enhancer and antagonizing NF-κB at inflammatory gene loci.\",\n      \"evidence\": \"ChIP for p53 at NR4A3 promoter and NR4A3-Bcl-2 co-IP (p53 axis); ChIP-seq and conditional double KO in HSCs (Cebpa/NF-κB axis)\",\n      \"pmids\": [\"30455429\", \"29343483\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether p53-NR4A3 axis operates in leukemia suppression in vivo\", \"Relative contributions of Cebpa activation versus NF-κB antagonism to HSC quiescence not quantified\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"NR4A3 was shown to direct monocyte-to-MoDC differentiation fate and to negatively regulate β-cell mass by inducing apoptosis under inflammatory conditions, illustrating its context-dependent pro-apoptotic versus differentiation functions.\",\n      \"evidence\": \"Nr4a3−/− mice with LPS challenge and bacterial infection (MoDC); Nr4a3 KO mice with β-cell mass quantification, overexpression/knockdown in INS cells and human islets\",\n      \"pmids\": [\"31285338\", \"30696767\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct transcriptional targets driving MoDC versus macrophage fate choice not identified\", \"Whether β-cell apoptotic function involves mitochondrial translocation not tested\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"NR4A3 deficiency in CD8+ T cells revealed that NR4A3 normally programs effector differentiation at the expense of memory: its loss increased chromatin accessibility at bZIP/AP-1 motifs and enhanced memory precursor generation.\",\n      \"evidence\": \"NR4A3-deficient murine CD8+ T cells with ATAC-seq, transcriptional profiling, and cytokine assays\",\n      \"pmids\": [\"32913051\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether NR4A3 directly binds and represses memory-associated loci or acts indirectly\", \"Interaction with NR4A1 in T cell fate decisions not dissected\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Dual PRDM1/NR4A3 CRISPR knockout in CAR T cells reduced exhaustion and improved antitumor efficacy, positioning NR4A3 as a targetable node in NFAT-driven T cell dysfunction.\",\n      \"evidence\": \"CRISPR KO in CAR T cells, scRNA-seq, in vivo tumor models\",\n      \"pmids\": [\"36350986\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether NR4A3 deletion alone is sufficient for durable CAR T improvement\", \"Mechanism of NFAT-NR4A3 transcriptional feedback not fully defined\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"NR4A3 was found to drive vascular calcification through a metabolic-epigenetic cascade: direct binding to ALDOA/PFKL promoters enhances glycolysis and lactate production, which promotes histone lactylation and downstream PHOSPHO1 activation.\",\n      \"evidence\": \"CUT&TAG chromatin occupancy, NR4A3−/− mice with medial arterial calcification models, glycolysis/lactate assays, RNA-seq\",\n      \"pmids\": [\"38629274\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether this glycolysis–lactylation axis operates in other NR4A3-expressing tissues\", \"Structural basis for NR4A3 selectivity at ALDOA versus other glycolytic gene promoters unknown\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"A unifying mechanistic framework explaining how NR4A3 switches between pro-proliferative (β-cells, salivary gland), anti-proliferative (HSCs), and pro-apoptotic (thymocytes, cancer) outputs in different cellular contexts remains undefined.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No structural model of full-length NR4A3 exists\", \"Endogenous physiological ligand(s) remain debated\", \"How post-translational modifications (PKC phosphorylation, m6A on mRNA) are integrated to determine nuclear versus mitochondrial function is unresolved\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0003677\", \"supporting_discovery_ids\": [1, 5, 11, 18, 20, 24]},\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [1, 5, 7, 8, 11, 18, 20, 22, 24]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [6, 10, 15, 29]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [1, 5, 6, 11, 18, 24]},\n      {\"term_id\": \"GO:0005739\", \"supporting_discovery_ids\": [6, 10]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [1, 5, 7, 11, 18, 20, 22, 24]},\n      {\"term_id\": \"R-HSA-5357801\", \"supporting_discovery_ids\": [0, 6, 10, 17]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [12, 13, 14, 15, 26, 30]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [0, 9, 11, 22]},\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [21, 24]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [2, 5, 29]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\n      \"BCL2\",\n      \"PARP1\",\n      \"SIX3\",\n      \"NR4A1\",\n      \"FOXO1\",\n      \"KLF2\",\n      \"KLF4\",\n      \"FOXA1\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}